



Cite this: *Chem. Soc. Rev.*, 2025, 54, 2948

Natural, modified and conjugated carbohydrates in nucleic acids

Debashis Dhara,^{ab} Laurence A. Mulard ^b and Marcel Hollenstein ^{*a}

Storage of genetic information in DNA occurs through a unique ordering of canonical base pairs. However, this would not be possible in the absence of the sugar–phosphate backbone which is essential for duplex formation. While over a hundred nucleobase modifications have been identified (mainly in RNA), Nature is rather conservative when it comes to alterations at the level of the (deoxy)ribose sugar moiety. This trend is not reflected in synthetic analogues of nucleic acids where modifications of the sugar entity is commonplace to improve the properties of DNA and RNA. In this review article, we describe the main incentives behind sugar modifications in nucleic acids and we highlight recent progress in this field with a particular emphasis on therapeutic applications, the development of xeno-nucleic acids (XNAs), and on interrogating nucleic acid etiology. We also describe recent strategies to conjugate carbohydrates and oligosaccharides to oligonucleotides since this represents a particularly powerful strategy to improve the therapeutic index of oligonucleotide drugs. The advent of glycoRNAs combined with progress in nucleic acid and carbohydrate chemistry, protein engineering, and delivery methods will undoubtedly yield more potent sugar-modified nucleic acids for therapeutic, biotechnological, and synthetic biology applications.

Received 3rd September 2024

DOI: 10.1039/d4cs00799a

rsc.li/chem-soc-rev

1. Introduction

Oligonucleotides are one of the most important classes of biomolecules that are present in all domains of life. DNA serves as the storage of genetic information while RNA relays this information to the protein synthesis machinery. Both DNA and RNA are made of nucleotide building blocks consisting of a phosphate backbone, a pentose, and a heterocyclic nucleobase (Fig. 1). Besides these structural key features, DNA and RNA can be transiently modified mainly at the level of the nucleobase. These epigenetic modifications allow regulation and alteration of gene expression without requiring a change in the sequence composition.^{1–5} Interestingly, so far, over 160 such chemical alterations have been identified in RNA and 17 in DNA.¹ These modifications range from simple methylation patterns to more intricate substitution patterns.^{6–9} On the other hand, naturally occurring chemical modifications at the level of the sugar unit are rather scarce and are mainly restricted to the 2'-position of the ribose moiety.^{10–12} This dearth of chemical diversity of the sugar unit is in stark contrast with the chemical and structural

diversity present in natural mono- and oligosaccharides.^{13,14} Another intriguing question is Nature's choice of five- rather than six-membered sugar building blocks.^{15–18}

This question can be addressed by synthesizing nucleic acid analogues with building blocks containing modified sugar moieties and comparing their chemical, biochemical, and structural properties to those of canonical DNA and RNA. Experiments towards this aim, pioneered by Albert Eschenmoser, have shown that the furanose plays an important role in maintaining an adequate structure for helix formation by imposing conformational restraints on nucleotides and represents the best balance between duplex stability, structural diversity and flexibility.^{19,20} On the other hand, six-membered hexopyranosyl-(4' → 6') oligonucleotides (homo-DNA; *vide infra*) display much stronger Watson–Crick base pairing capacities than their natural, five-membered ring containing counterparts and are unable to interact with canonical DNA and RNA.¹⁶ The origin of the enhanced thermodynamic stability of homo-DNA is believed to be entropic in nature and to originate from the higher rigidity imposed by the pyranose ring.¹⁶ These studies aiming at understanding the origin of the structure of nucleic acids have spearheaded an immense research activity striving to improve the stability of oligonucleotides in biological media.

Chemical modification of nucleic acids originally stems from the advent of the antisense oligonucleotide therapeutic strategy. Antisense oligonucleotides (ASOs) consist of short

^a Department of Structural Biology and Chemistry, Laboratory for Bioorganic Chemistry of Nucleic Acids, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, 28, rue du Docteur Roux, 75724 Paris Cedex 15, France.

E-mail: marcel.hollenstein@pasteur.fr

^b Department of Structural Biology and Chemistry, Laboratory for Chemistry of Biomolecules, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, 28, rue du Docteur Roux, 75724 Paris Cedex 15, France



sequences of DNA or RNA that are designed to recognize specific mRNA target regions and either sterically block the protein machinery or recruit endonucleases to hydrolyze mRNA.^{21–27} In the absence of chemical modifications, short oligonucleotides are rapidly degraded by nucleases, suffer from high renal excretion and poor cellular penetration, and often induce important off-target binding toxicities.^{28–34} Alleviation of these shortcomings can be achieved for instance by altering the chemical nature of the sugar moiety of nucleotides or coupling to ligands that act as vectors carrying oligonucleotides to their targets.^{11,35–39} Inspired by the chemistry of nucleic acids both to improve the therapeutic efficiency of oligonucleotides and understanding of the chemical etiology of the nucleic acid structure, a new research field was born which strives to



Debashis Dhara

2023). His research focuses on carbohydrates, nucleic acids, glycoconjugate vaccines, therapeutic oligonucleotides, and sustainable chemistry.



Laurence A. Mular

peptide science or glycoscience, her research interests focus on the development of chemical tools and bioactive compounds aimed at studying and interfering with molecular phenomena governing infectious diseases. The focus is on peptide/carbohydrate-based diversity oriented synthesis and bioconjugates, on investigating synthetic glycans as surrogates of bacterial polysaccharides, and on advancing synthetic carbohydrate-based conjugate vaccines up to clinics.

identify artificial genetic polymers called xenonucleic acids (XNAs).^{20,40–44} XNAs differ from their natural counterparts DNA and RNA by the nature of the sugar moiety solely and retain the structure of the original nucleobases (*i.e.* A, C, G, and T) and phosphodiester linkages found in canonical nucleic acids (Fig. 1).⁴⁰ Such a chemical differentiation allows XNAs to store genetic information while eluding interaction with DNA or RNA.

Besides the choice for furanoses rather than pyranoses as salient structural elements of nucleotides, glycosylation of nucleic acids is another, fundamental question that still needs to be further addressed. Until the recent discovery that certain small, non-coding RNAs were found to be equipped with sialylated glycans,⁴⁵ it was believed that glycosylation did not affect nucleic acids. This is in stark contrast with all other natural biopolymers since glycosylation is one of the most common post-transcriptional modifications of proteins^{14,46} and glycolipids play important roles in numerous cellular processes.^{14,47}

Overall, these considerations highlight the presence of an intricate and deep interconnection between nucleic acids and carbohydrates. In this review article, we describe the nature and properties of carbohydrate-modified nucleic acids. In the first section, we highlight recent progress made towards the synthesis of nucleosides and nucleotides with modified sugar residues for the improvement of the *in vivo* properties of therapeutic oligonucleotides and the development of orthogonal XNAs. In the second section, we discuss nucleic acid modification with glycans and in the last section, we summarize progress on the conjugation of carbohydrates and (poly)saccharides to oligonucleotides. This review article, however, addresses modifications of phosphate and/or nucleobases other than carbohydrates, and the interested reader is redirected to recent reviews covering these aspects.^{37,42,48–50}



Marcel Hollenstein

Marcel Hollenstein received his PhD in Chemistry (2004) from the University of Bern (Switzerland) under the supervision of Prof. Christian Leumann. He then moved to the group of Prof. David Perrin (University of British Columbia, Vancouver) as a postdoctoral fellow. In 2009, he moved back to the University of Bern as a Swiss National Science Foundation Ambizione Fellow. He then moved to Institut Pasteur in Paris, France where he was first an independent junior research group leader (2016–2022) and then a senior research group leader (from 2022 on). Research activities in his lab focus on the selection of modified aptamers, the enzymatic synthesis of modified nucleic acids, and the development of biocatalytic approaches for the synthesis of modified oligonucleotides, particularly with therapeutically relevant modifications.







Fig. 1 Top: Structures of nucleobases. Bottom: Representation of nucleic acids and their scope of various modifications.

2. Chemical modification of the (deoxy)ribose of nucleosides and nucleotides

Each unit of the backbone of natural nucleic acids consists of six-covalent bonds (except for 2'-5'-branched RNA which contains seven bonds⁵¹). Changes in the backbone induce important alterations in the sugar pucker conformation which in turn can affect the base pairing strength and thus the (bio) physical/chemical properties of duplexes. In addition, the Watson–Crick base pairing rule (*i.e.* pairs with T (U) and G with C) governs most of the fundamental properties of DNA and RNA and modifying the structure of the backbone of DNA/RNA building blocks can alter the hydrogen bonding capacity and hence duplex stability.^{19,52,53} On the other hand, the ribose/deoxyribose is the main constituting part of nucleic acids involved in creating structural and functional diversity, and thus their chemical modification can lead to analogues with improved functional and/or biological properties. Indeed, changing the nature of the sugar moiety can improve the resistance against nuclelease-mediated degradation, modulate or lock the conformation of the sugar puckering to reduce entropic penalty upon duplex formation, target binding efficiency and specificity, favor cellular penetration, and improve pharmacokinetics of nucleic acid drugs.

Realization of the tremendous possibilities offered by sugar alterations, especially in the context of developing more potent therapeutic agents, stimulated intensive research activities. At first, chemical alterations consisted in minute changes of the (deoxy)ribose. For instance, replacing the 2'-OH of ribose with NH₂, 2'-methoxy (2'-OMe, 2), fluorine (2'-F, 3), methoxyethyl (2'-MOE, 4), and aminopropyl (2'-O-AP) led to the development of potent first-generation chemistries that have been included in a number of therapeutic oligonucleotides such as antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs)

(Fig. 2).^{37,39,54,55} In addition to these rather minor alterations, more drastic modifications can be made to the backbone by changing the nature of the sugar moiety to trioses, tetroses, other pentoses, hexoses including pyranose and furanose forms or even seven-membered sugar rings (Fig. 3).^{41,56}

Such alterations of the natural ribose/deoxyribose can improve the properties of therapeutic oligonucleotides but also confer a certain degree of orthogonality to canonical nucleic acids which is one of the main prerequisites for the crafting of XNAs.^{20,40,42,43} In this section, we emphasize the main artificial sugar scaffolds that have been integrated into oligonucleotides and their effect on duplex/triplex stability and potential usefulness in practical applications. Interested readers on the topic of other therapeutic relevant modifications (*e.g.* at the level of phosphate) are redirected to recent review articles of this field.^{25,26,37,39,55,57–60}

2.1 Glycol nucleic acid (GNA)

The sugar unit of nucleic acids can be replaced by short spacers such as glycerol. Indeed, in glycol nucleic acid (GNA) the (deoxy)ribose is replaced by a more flexible, acyclic glycol-phosphate backbone which lacks one bond compared to canonical DNA/RNA (6 in Fig. 3).^{61–65} In addition, the 2,3-dihydroxypropyl-based scaffold of GNA is reminiscent of the triose glyceraldehyde and can thus be considered as the smallest possible XNA scaffold.⁶⁶ Even though the connecting glycerol moiety in GNA is achiral, it is also prochiral with respect to substitution at the primary hydroxyl group. Hence, there are two diastereoisomers of GNA (6), namely (*R*)-GNA and (*S*)-GNA (Fig. 4). Oligomers formed by both (*S*)- and (*R*)-GNA form antiparallel self-pairs that display highly improved thermal stabilities compared to the corresponding, unmodified RNA and DNA duplexes (ΔT_m of 22 °C and 20 °C, respectively).⁶⁴ This result is remarkable considering the fact that the GNA backbone is acyclic and hence markedly deviates from the structure of ribose/deoxyribose. However, (*S*)-GNA and (*R*)-GNA oligomers do not undergo antiparallel cross-pairing with each other and fail to form duplexes with complementary DNA sequences. Interestingly, only (*S*)-GNA is






Fig. 3 Chemical structures of representative, modified carbohydrate backbones used as DNA and RNA analogues (blue highlighting indicates six bond backbone units and green highlighting indicates altered backbone units).




Fig. 4 Chemical structures of (R)-GNA and (S)-GNA (6), D- and L-aTNA (13), and SNA (14). The color code highlights structural differences between members of acyclic nucleic acid analogues.

capable of cross-pairing with complementary RNA and follows canonical Watson–Crick base pairing rules. Overall, the combination of structural simplicity and enhanced thermal stability of

GNA (6) makes this modification an attractive scaffold for the crafting of therapeutic agents.⁶²

Storage of genetic information and retrieving thereof rely on the possibility of enzymatically synthesizing and replicating nucleic acid polymers.⁶⁷ This important prerequisite is only met when stable duplexes are formed and when polymerases can efficiently read through and faithfully copy the information encoded in template sequences by incorporating the correct (deoxy)nucleoside monophosphates ((d)NMPs) into primers. Interestingly, even though GNA and DNA do not form stable duplexes, DNA polymerases such as *Bst* are capable of catalyzing DNA synthesis on short dodecamer GNA templates.⁶⁸ GNA triphosphates on the other hand are only moderately tolerated by the terminator polymerase since DNA primers are extended by only a few glycol nucleotides.⁶⁹

The favorable assets of GNA spawned the design of other acyclic DNA analogues such as ZNA (which consists of a phosphonate rather than a phosphate connector and has an additional methylene unit compared to GNA),⁷⁰ acyclic D- and L-threoninol nucleic acid (D- and L-aTNA, 13 in Fig. 4)^{71,72} and serinol nucleic acid (SNA, 14 in Fig. 4)⁷³ which also form highly stable homo-duplexes but display a higher propensity to form stable duplexes with DNA and RNA than GNA.⁷⁴ Interestingly, the methyl group dictates the stereochemistry in aTNA (13) monomers, oligomers, and duplexes. In the absence of this




Fig. 5 Chemical structures of GNA equipped with glucose-nucleobase surrogates and schematic representation of the putative H-bonding interaction between 6-deoxyglucose in **16** and deoxyguanine in duplex DNA (**16:dG**). The modified oligonucleotides comprise in particular (S)-2,3-dihydroxypropyl glucose (**15**), (S)-2,3-dihydroxypropyl 6-deoxyglucose (**16**), (S)-2,3-dihydroxypropyl permethylated glucose (**17**), (R)-2,3-dihydroxypropyl permethylated glucose (**18**), and (S)-1,4-dihydroxybutyl-2-(6-deoxyglucose) (**19**).

kind of methyl moiety, the stereochemistry is only controlled by the sequence in SNA (**14**) oligomers.⁷³ Nonetheless, GNA and related analogues are interesting scaffolds for the development of bio-orthogonal genetic systems (XNAs) since they fulfill most of the requirements.⁷⁰

2.1.1 GNA equipped with glucose–nucleobase pseudo base pairs. In addition to therapeutic applications and the development of orthogonal and synthetic genetic systems, GNAs have also been instrumental in the study of non-covalent forces between different types of biomolecules. Indeed, glucose and 6-deoxyglucose have been examined as a carbohydrate–nucleobase pairing system when incorporated on a GNA scaffold (**15–19** in Fig. 5).⁷⁵ The resulting double helices, either in the DNA or GNA series, are less stable than the corresponding systems equipped with canonical nucleobases but do not induce any marked changes in the three-dimensional structure of the duplexes. Particularly, a 6-deoxyglucose nucleobase surrogate is fully integrated within a double helix and forms two hydrogen bonds with complementary guanine or thymine (dG:**16** in Fig. 5). Changing the anchoring system from glycerol to the one carbon longer butanetriol system did not permit an increase in the thermal stability of the duplexes.⁷⁶ Moreover, Kf (exo⁻) polymerase from *Escherichia coli* mainly incorporated purine nucleotides (~20% dAMP and to a lesser extent dGMP) opposite a templating acyclic nucleotide equipped with glucose and 6-deoxyglucose.⁷⁶ Other DNA polymerases such as *Bst* 2.0, SIII and BIOTAQ seem to display a loop-out mechanism and mainly incorporated dTMP.

2.2 Three-membered ring analogues

The smallest possible cyclic surrogate of the deoxyribose/ribose moiety is a three-membered cyclopropane ring. Such a three-membered ring system is heavily strained and displays an intermediate sp³- and sp²-hybridization on the constituting carbon atoms.⁷⁷ Consequently, substitution of the (deoxy)ribose moiety by cyclopropane imparts a near-linear ring structure as well as a strong rigidity to the scaffold.^{78,79} These alluring structural and




Fig. 6 Chemical structures of cyclopropyl nucleoside analogues. **A** (\pm)-2,2-bis(hydroxymethyl)cyclopropyl nucleoside **20** and **B** synadenol **21**.

chemical features have attracted attention for the development of potent antiviral nucleosides. Nonetheless, the properties of the cyclopropyl ring system did not hold to promises and the antiviral activity of such analogues (see *e.g.* nucleoside **20** in Fig. 6) was usually low to moderate.^{78–80} A noticeable exception is synadenol (**21** in Fig. 6) and the corresponding guanosine analogue, synguanol, which display important antiviral activity against human cytomegalovirus and the Epstein–Barr virus.^{81,82} So far, cyclopropyl nucleosides have not been introduced into nucleic acids by solid-phase oligonucleotide synthesis (SPOS) and all nucleotides with this altered sugar moiety were designed to inhibit polymerases and transcriptases.^{83–85}

2.3 Four-membered ring analogues

Increasing the ring size by a single carbon atom results in cyclobutyl-containing nucleoside analogues which, unlike their three-membered counterparts, often display interesting antiviral properties. For instance, such an altered scaffold has been identified in the naturally occurring antiviral agent oxetanocin A (**7** in Fig. 3 and **22** in Fig. 7)⁸⁶ which acts as a DNA chain




Fig. 7 Chemical structures of four membered ring containing nucleosides, nucleotides, and oligonucleotides.



terminator.⁸⁷⁻⁸⁹ The unusual three-dimensional structure conveyed by the presence of the oxetane motif⁹⁰ combined with its highly potent pharmacological properties have led to the synthesis of numerous oxetanocin variants including carbacylic 25 (Fig. 7) and 3'-substituted analogues (23 in Fig. 7).⁸⁶ In the 1990s, Katagiri and colleagues have reported the synthesis of oligonucleotides containing oxetanocin nucleotides. Homopolymeric dodecamers containing oxetanocin analogues (24 in Fig. 7) formed duplexes with complementary DNA sequences albeit with a marked thermal destabilization ($\Delta T_m \sim -7$ °C per modification).⁹¹ Interestingly, when the ring oxygen was replaced by a carbon atom (25 in Fig. 7), the oligomer properties changed drastically.⁹² Indeed, homopolymers containing enantiomeric carbocyclic oxetanocin nucleotides display a strong tendency to form stable triple helices with complementary DNA and RNA sequences even under low salt conditions. These modified oligonucleotides feature an extended seven-bond backbone and display a more marked preference for RNA than DNA.^{92,93} Finally, monophosphorylated oxetanocin species have been reported in the literature (22 in Fig. 7).⁸⁹ Nucleoside triphosphates might thus be accessible and when combined with engineered polymerases, enzymatic synthesis of oxetanocin oligonucleotides could be envisioned in the future. Such nucleotide analogues represent alluring alternatives for the construction of XNA systems.

2.3 Five-membered ring analogues

The most common and intuitive approach for the generation of nucleic acid analogues consists in either decorating the pentose with additional and/or different substituents or by changing the nature of the sugar without altering the size of the ring. Such modification patterns allow for fine tuning of the sugar pucker as well as improving the *in vivo* properties of the ensuing analogues without deviating substantially from the structure of canonical nucleic acids.⁵² In this section, we will discuss the most relevant examples of both approaches.

2.3.1 Ribofuranosyl nucleic acid analogues

C2'-modifications. The chemical/biological differences between DNA and RNA arise from the presence of a 2'-OH or substituent on the ribose moiety. Chemical alteration at the C2' position is a potent strategy to increase the biological stability of therapeutic oligonucleotides. Currently, all FDA-approved or in late stage clinical trials oligonucleotide drugs are fully modified at the C2'-position.^{37,39,55} In addition to improved biological stability, appendage of electron withdrawing substituents at the 2'-position will favor a C3'-*endo* (North type) conformation while a C2'-*endo* (South type) sugar pucker is favored in DNA or constrained systems such as locked nucleic acids (*vide infra*). Lastly, depending on the nature of the C2'-substituent, the binding affinity to target RNA can also be improved by this simple modification pattern.

Amongst the C2'-substituents, 2'-fluorine is one of the most popular and effective modifications (3 in Fig. 2). The 2'-fluorine substituent induces a strong *gauche* effect which is reflected by a marked preference for a C3'-*endo* sugar pucker. RNA oligonucleotides equipped with 2'-fluoro riboses display enhanced thermal duplex stabilities when paired with complementary RNA sequences (ΔT_m of +2 to 3 °C per modification).⁹⁴ This

enhancement in thermal stability is presumably caused by an enthalpic gain generated by favorable stacking interactions and base-pairing due the presence of the electronegative substituent.^{95,96} Expectedly, the presence of 2'-fluoro modifications also offers a strong resistance to nucleases both *in vitro* and *in vivo*.^{96,97} Nonetheless, the multiple advantageous assets of 2'-fluoro-modified RNAs are impinged by unfavorable pharmacokinetic properties.^{98,99}

Replacement of the 2'-hydroxy moieties with 2'-OMe is another potent strategy to increase nuclease resistance and binding affinity, and also to reduce the immune response to therapeutic nucleic acids (2 in Fig. 2).^{100,101} As for the 2'-F substituent, the presence of a methoxy moiety at the C2' raises duplex stability (ΔT_m of +1 °C per modification) and locks the sugar pucker in a C3'-*endo* conformation. The increase of stabilization is caused by favorable hydrophobic interactions of the methoxy moiety in the duplex minor groove and by reduced entropic penalty upon duplex formation due to partial pre-organization of the sugar pucker.^{58,101-104} Given the favorable properties of the 2'-OMe modification strategy, most FDA-approved oligonucleotide therapeutics contain such nucleotide analogues.³⁹

The 2'-OMe represents the smallest of all 2'-O-alkyl modifications reported to date. With the exception of 2'-MOE (4 in Fig. 2), it is also the most efficient in terms of improvement of RNA biological and therapeutic properties. Indeed, when the size of the alkyl moiety was varied from 2'-OMe to larger units such as 2'-O-ethyl, 2'-O-propyl, 2'-O-butyl, 2'-O-pentyl, and 2'-O-nonyl (28 in Fig. 8), a clear correlation was observed for the stability of DNA-RNA duplexes with the smaller substituents stabilizing and larger substituents destabilizing the duplex, respectively.^{105,106} Nuclease resistance increases with the size of the 2'-O-alkyl chain, suggesting that fine-tuning of the bulkiness and length of the 2'-O-modification can produce an adequate mix of thermal stability and nuclease resistance.¹⁰¹ However, these observations are also sequence-dependent since the presence of a 3'-terminal 2'-O-[2-(benzyloxy)ethyl] substituent (31 in Fig. 8) is rapidly degraded by exonucleases despite its rather important size.¹⁰⁶

Over the past decades, the effect of a vast number of other substituents at the C2'-position has been explored (structures




Fig. 8 Chemical structures of modification patterns at the level of the 2'-O-position of ribose.



26–31 in Fig. 8¹⁰⁷ including 2'-*O*-alkyl, 2'-*O*-alkyl ether,^{108,109} 2'-*O*-amino alkyls,^{110,111} 2'-*O*-ethylene glycol or 2'-*O*-glycerol,¹¹² 2'-*O*-carbamate,¹¹³ 2'-*O*-(*N*-methylcarbamate),¹¹⁴ 2'-*O*-allyl/alkenyl,¹⁰⁶ 2'-*O*-aminohexyl,¹¹⁵ and 2'-*O*-(2-(methylthio)ethyl).¹¹⁶

Amongst all the modifications that have been explored, the 2'-MOE substitution pattern displays the best balance between nuclease resistance and induced thermal stability (ΔT_m of +1 to 2 °C per modification).^{112,117} While less pronounced than in the case of 2'-fluoro, these properties arise in part due to an additional conformational pre-organization imparted by the *gauche* effect due to the impaired rotation around the ethylene carbon–carbon bond.¹¹⁸ Hence, 2'-MOE substitution has advanced as a popular, second generation modification found in many therapeutic oligonucleotides.³⁹

In terms of synthesis, C2'-modified nucleotides can be introduced by SPOS using activated phosphoramidite building blocks but also by enzymatic, polymerase-mediated synthesis. Indeed, some wild-type polymerases such as the T7 RNA polymerase or RNA polymerases with terminal transferase activity do have a propensity for accepting ribonucleotides equipped with C2'-substituents.^{119–123} Nonetheless, this capability remains limited and engineered polymerases are required to tolerate bulkier modifications such as 2'-MOE and achieve efficient synthesis.^{124–127} In order to alleviate these synthetic limitations, alternative chemoenzymatic methods involving for instance ligases are currently in development.^{108,128–130}

Modifications at positions C2' and C4' of the ribose. The simultaneous introduction of substituents at the C2' and C4' positions was also explored even though not as extensively as single 2'-*O*-modifications.

Nuclease resistance of oligonucleotides can also be improved by introducing chemical modifications at C4'. This is because modifications at this position can insert between the 3',5'-phosphodiesters and thus hinder cleavage activity mediated by nucleases.¹³¹ C4'-substitution also changes the sugar puckering and shifts towards a North-East conformation are often observed.¹³²

Recently, several C4'-modified ribonucleotides were incorporated into RNA sequences and their effect on biostability and thermal stability was assessed. Prominent examples include 4'-*C*-methyl-2'-deoxy-2'-fluoro (32 in Fig. 9),¹³³ 4'-*C*-methoxy-2'-deoxy-2'-fluoro (33),¹³² 4'-*C*-aminomethyl-2'-*O*-methyl (34 with $n = 1$),¹³⁴ 4'-*C*-aminoalkyl-2'-*O*-methyl (34),¹³⁵ 4'-*C*-aminoalkyl-2'-*O*-fluoro (34 with $n = 1$ –3),¹³⁶ 4'-*C*-guanidinomethyl-2'-*O*-methyl (35),¹³⁷ 4'-*C*-guanidinocarbohydrazidomethyl-5-methyl (36),¹³⁸ and (*S*)-5'-*C*-aminopropyl-2'-*O*-methyl¹³⁹ (37). Collectively, these modifications induced a strong protection against nuclease-mediated degradation and were well-tolerated within RNA duplexes. Importantly, this modification pattern does not interfere with siRNA-mediated gene silencing activity and interacts favorably with human Argonaute 2 (Ago-2).¹³³ These studies suggest that C2'/C4'-dual modification patterns represent alternative scaffolds that can be implemented in oligonucleotide therapeutics. Such nucleotide analogues also display potent antiviral activity as showcased by a nucleoside triphosphate




Fig. 9 Modifications at the 2'- and 4'-C-positions of the ribose.

equipped with fluorine substituents at the C2'- and C4'-positions which efficiently inhibited RNA synthesis by acting as a chain terminator.¹⁴⁰

Instead of modifying the ribose moiety by appending additional functional groups at position C4', the O4' oxygen atom can be substituted by other heteroelements (Fig. 10). In this context, Matsuda *et al.* first reported the synthesis of 4'-thio-2'-deoxyribonucleosides (38) and 4'-thioribonucleosides (39).^{141,142} After conversion to phosphoramidite building blocks and incorporation into oligonucleotides by SPOS, 4'-thio-modified DNA and RNA were shown to increase nuclease resistance and thermal stability of duplexes with complementary sequences.^{143,144}

Later, the same group synthesized and characterized the properties of 2'-modified-4'-thio-RNAs.¹⁴⁵ In a comprehensive study, the authors demonstrated that 2'-fluoro-4'-thio-RNA (40) showed an impressive increase in thermal stability (ΔT_m of +16 °C) with complementary RNA compared to an unmodified RNA duplex. In addition, 2'-fluoro-4'-thio-RNA (40) and 2'-OMe-4'-thio-RNA (41) sequences preferred binding to complementary




Fig. 10 Modifications at the 2'-C and 4'-O-positions.



RNA rather than DNA. Lastly, 2'-OMe-4'-thio-RNA (**41**) displayed improved resistance against endo- and exonuclease-mediated degradation when compared to oligonucleotides decorated with other modifications (*i.e.* 2'-fluoro, 2'-fluoro-4'-thio, 2'-OMe-4'-thio, and 4'-thio) or natural DNA and RNA.¹⁴⁵

Besides SPOS, 4'-thio-modified ribo- and deoxyribonucleotides are well-tolerated by polymerases and can thus be incorporated enzymatically into oligonucleotides.^{146–149} Interestingly, the corresponding nucleoside triphosphate, 4'-seleno-TPP, was prepared and could be incorporated into DNA using various polymerases, albeit with reduced efficiency compared to the corresponding 4'-thio nucleotide or unmodified dTTP.¹⁵⁰

Carbocyclic nucleosides have increased chemical and metabolic stability compared to natural nucleosides. They are unaffected by phosphorylases and hydrolases due to the absence of glycosidic bonds. This important feature has been exploited for the construction of numerous nucleoside antiviral agents,⁷⁸ some of which (*e.g.* 2'-deoxyaristeromycin,¹⁵¹ **42** in Fig. 10) have been incorporated into oligonucleotides by SPOS. In addition, carbocyclic analogues can also be used to improve the properties of therapeutic oligonucleotides. Indeed, the inclusion of such analogues into DNA sequences mostly results in duplexes with improved thermal stability.^{152,153} The additional degree of stabilization provided by a C2'-carbocyclic nucleotide containing oligonucleotides mainly results from a preferred North-type conformation of the cyclopentane moieties which imposes an A-like conformation on the duplexes.¹⁵⁴

The nuclease resistance of carbocyclic-modified oligonucleotides can be further fine-tuned by the addition of substituents at position C6' of the carbacyclic unit and/or at position C2'.¹⁵⁵ To prove this hypothesis, Altmann *et al.* prepared a series of DNA oligonucleotides equipped with 2'- or 6'-alkoxy substituted carbocyclic nucleotide units (**43**) and evaluated their binding affinity to complementary RNA as well as their resistance to nucleases.¹⁵⁵ The presence of both types of substitution patterns led to decreased thermal stability of the resulting duplexes, but as expected, the presence of an additional 6'-substituent massively increased biostability.

The last realistic heteroelement exchange possible on a five-membered ring system is swapping oxygen with a nitrogen atom. Many iminoribitol containing nucleoside and nucleotide analogues such as immucilin A (**44** in Fig. 10) are good inhibitors of various enzymes because they are good transition state mimics. Yet, they have barely been incorporated into nucleic acids by SPOS.^{156–159} Related to iminoribitol are the pyrrolidine C-nucleoside analogues developed by the Leumann group (**45** in Fig. 10). Such analogues were conceived to enhance the properties of triplex forming oligonucleotides (in the context of the antogene strategy¹⁶⁰), particularly their capacity at recognizing duplexes *via* salt bridge formation.^{161,162}

Combination of 2'-O- and 5'-C/O-ribose modifications. As mentioned previously, an important prerequisite for the development of efficient RNA/DNA therapeutics is biological stability. In particular, this implies that the nucleotidic scaffold needs to be chemically altered to resist against the hydrolytic degradation

mediated predominantly by 3'-exonucleases.^{163,164} In addition, the presence of a high density of negative charges carried by the phosphate linkages denies oligonucleotides from penetrating cellular membranes. In order to alleviate these shortcomings, a number of modifications were introduced at the level of the phosphodiester moiety. An important example is 5'-methyl-DNA (5'-Me-DNA) where an additional methyl moiety was introduced at position 5' (**46** and **47** in Fig. 11).¹⁶⁵ The presence of such a substituent reduces recognition by nucleases and does not alter the propensity of base pairing with complementary sequences (ΔT_m of -1 to -3 °C per modification). Interestingly, unlike phosphorothioates or methylphosphates, the chiral center in 5'-Me-DNA is not located on the phosphorous atom but on the vicinal carbon atom of the sugar moiety, whose stereochemistry can be controlled.¹⁶⁶ A similar strategy was applied to locked nucleic acids (LNA) where the effect of a 5'-(*S*)-methyl group (**48**) was shown to be beneficial for the recognition of complementary sequences, while the exact opposite was observed in sequences containing (*R*)-substituents (**49**).¹⁶⁷

Obviously, the nature of the 5'-substituent is not restricted to a short methyl moiety. In a recent work by Prakash and colleagues various 5'-C-modification patterns were introduced in a stereoselective manner and the resulting ribonucleosides were introduced into siRNA sequences by SPOS (**50** in Fig. 11). This bulk of work demonstrated that a single stranded siRNA (ss-siRNA) sequence equipped with a single (*R*)-methyl group located on the first nucleotide (*i.e.* at the 5'-end of the sequence) displayed a more potent gene silencing activity than the corresponding sequence modified with an (*S*)-methyl group. This differential activity is presumably caused by the conformational preference around the torsion angle γ which is in a favorable *ap* range in the (*R*)-isomer. Interestingly, various substituents of larger steric bulk than a short methyl group were well-tolerated and did not negatively affect the gene silencing activity of both modified ss-siRNAs and siRNAs. On the other hand, introducing side-chains with anionic or cationic characteristics was detrimental for the activity of ss-siRNAs but not




Fig. 11 Modification at the 2'-O, 5'-C position of ribose and internucleotidic modification patterns.



for that of siRNAs. This negative impact was deemed to originate either from negative charge repulsion or salt bridge formation with critical amino acid residues in the binding pocket of Ago-2.¹⁶⁸

Numerous synthetic campaigns have been directed at modifying the internucleosidic linkage.¹⁶⁹ For instance, a simple 5'-O to 5'-CH₂ transposition results in the installation of a phosphonate backbone (51). The introduction of such a phosphodiester isostere improved the biostability of oligonucleotides but led to a destabilization of duplexes ($\Delta T_m \sim -3$ °C per modification).¹⁷⁰ Increasing the length of the internucleosidic backbone either at the 3'- (52) or the 5'-termini (51) results in similar duplex destabilization.¹⁷¹ On the other hand, when the negatively charged phosphate is substituted with neutral mimics such as triazole (54),^{172,173} sulfamate (55),¹⁷⁴⁻¹⁷⁶ or amide (56),¹⁷⁷ or with positively charged alternatives such as amines (57),¹⁷⁸ both biostability and affinity for complementary sequences can be enhanced.

2.3.2 Arabinonucleic acid. Arabinose is the 2'-epimer of ribose where the 2'-OH is oriented *cis* rather than *trans* with respect to the nucleobase (9 in Fig. 3). Interest in arabinose analogues of nucleic acids (ANA) stems from early studies on cytosine arabinoside (araC) and the corresponding nucleoside triphosphate araCTP which are potent competitive inhibitors of DNA but not RNA polymerases.^{179,180} ANA oligonucleotides were synthesized for the first time by Damha *et al.* with the aim of understanding why Nature opted for ribose (as in RNA) rather than arabinose (as in ANA) as genetic biopolymers.^{181,182} These studies revealed that ANA oligonucleotides form duplexes with complementary RNA but induce a marked destabilization (ΔT_m values ranging from -1.0 to -1.5 °C per modification in mixmer sequences).¹⁸¹ Moreover, ANA sequences barely bind to complementary DNA. The change in stereochemistry at position 2' confers a DNA-like conformation to ANA (ANAs tend to adopt a C2'-*endo* pucker) while the presence of the bulkier hydroxyl moiety is believed to negatively impact base stacking and Watson–Crick base pairing efficiency which in turn explains the only moderate to low affinity of ANA for DNA. Overall, the binding affinity for complementary RNA sequences decreases in the order RNA > DNA > phosphorothioate–DNA > ANA. Despite low affinity for complementary DNA/RNA, ANAs have attracted attention as candidates in the antisense therapeutic approach because inversion of the stereochemistry at C2' was found to increase the resistance against degradation mediated by 3'-exonucleases. What is more, ANA-containing oligonucleotides are capable of recruiting RNase H to hydrolyze complementary RNA sequences which is an important prerequisite to be considered for the development of potential gene silencing agents.^{181,183} This property arises through a combination of the adequate DNA-like conformation of ANA/RNA duplexes with the positioning of the 2'-OH moieties in the major groove where it does not interfere with RNase H binding. Lastly, despite a poor capacity at interacting with ssDNA, ANAs can bind to duplex DNA and form relatively stable triple helices. In contrast, they do not bind to dsRNA or RNA/DNA duplexes.¹⁸⁴

ANA-modified oligonucleotides are mainly produced by SPOS since the corresponding arabinonucleoside triphosphates

are only poor substrates for naturally occurring archaeal DNA polymerases.¹⁸⁵ On the hand, various polymerases have been engineered to better tolerate arabinonucleotides and permit molecular evolution experiments to generate ANA-containing aptamers and enzymes.^{67,186-188}

2.3.3 Deoxyfluoro-arabinonucleic acid. In order to improve the pairing properties of ANA, the 2'-OH substituent was replaced by a smaller fluorine atom giving rise to 2'-deoxy-2'-fluoro-arabinonucleic acid (FANA; 58 in Fig. 12).¹⁸⁹⁻¹⁹² This subtle substitution confers FANA remarkable properties. For instance, FANA modified oligonucleotides form very stable duplexes with complementary RNA sequences ($\Delta T_m = +0.2$ to $+0.8$ °C per modification compared to unmodified DNA/RNA duplexes) which is in stark contrast with ANA.¹⁹² Remarkably, the stability of duplexes formed with complementary RNA decreases in the order FANA > RNA > DNA > phosphorothioate–DNA > ANA.^{192,193} In addition, FANAs form more stable duplexes with complementary DNA than the corresponding 2'-F-RNAs where the fluorine atom is of opposite stereochemistry. The structural consequences from replacing a 2'-OH with a corresponding 2'-fluorine on the arabinose are a shift from a C2'-*endo* pucker (ANA) to an O4'-*endo* conformation (FANA).^{181,194,195} In addition, the *gauche* effect caused by the interaction between the highly electronegative fluorine atom and the O4' of the sugar confers rigidity to the scaffold and hence locks FANA in the O4'-*endo* (East) conformation. This altered conformation allows FANA to be compatible both with RNA and DNA which is not the case for ANA. Interestingly, even though FANA cannot adopt Southern (C2'-*endo*) or South-Eastern (C1'-*exo*) sugar conformations which are observed in crystal structures of RNase H in complex with RNA/DNA duplexes, FANAs are even better at recruiting this enzyme than ANAs.¹⁹³ Overall, these favorable properties have led to the development of ASOs,^{196,197} siRNAs,^{198,199} and enzymes and gene editing tools based on the FANA scaffold.²⁰⁰⁻²⁰²

FANA-containing oligonucleotides can be obtained by the sequential assembly of phosphoramidite building blocks using SPOS but also enzymatically by the polymerase-mediated incorporation of the corresponding nucleoside triphosphates. Indeed, 2'-deoxy-2'-fluoro-arabinonucleoside triphosphates are tolerated as substrates by a number of Family B DNA polymerases such as 9°N and Vent (*exo*⁻).²⁰³⁻²⁰⁵ However, while these polymerases can be used for the construction of oligonucleotides containing FANA modifications, engineered polymerases need to be used to synthesize fully-modified FANA sequences.^{67,185} The possibility of enzymatic synthesis combined with the properties of this type




Fig. 12 Chemical structures of RNA, 2'-fluoro-RNA (3) and FANA (58).



of chemical modification have led to the identification of aptamers and XNAzymes by application of SELEX.^{67,185,186,206,207}

2.3.4 α -L-Threofuranosyl nucleic acid. The constituting sugar element of α -L-threofuranosyl nucleic acids (TNAs), α -L-threofuranose, contains only four carbon atoms and is the second simplest of all studied nucleic acid analogues (8 in Fig. 3).^{208,209} TNAs contain *trans* vicinal ($3' \rightarrow 2'$) phosphodiester bridges that can form stable antiparallel homo-duplexes. These TNA homo-duplexes have thermal stabilities which are comparable to those of canonical RNA and DNA duplexes. In addition, despite displaying a shorter backbone repeating unit, TNAs form also stable duplexes with complementary RNA and DNA sequences – with a preference for RNA.^{209–211} Overall, tetrose-based oligonucleotides strictly require an antiparallel orientation to form stable homo- and hetero-duplexes and while hairpin-like structures can form they are not as stable as those found in RNA.^{209,212} The preference for RNA is yet poorly understood but X-ray structure analysis of α -L-threofuranosyl nucleotides and TNA-DNA/RNA duplexes sheds light on how the shorter backbone accommodates into DNA and RNA oligonucleotides.^{211,213,214} In both L-threofuranosyl nucleotides and oligonucleotides, the conformation is C_4' -*exo* and the substituents at the 2' and 3' positions adopt a quasi-diaxial orientation with torsion angles comprised between 158° and 169° . Binding to complementary DNA is possible because the latter adjusts to the structural requirements imposed by the rigid backbone of TNA by reducing the interphosphate distance.²¹⁴ TNA homo-duplexes and TNA-DNA hetero-duplexes adopt an A-DNA conformation which might explain the preference for RNA over DNA.²¹⁴

Due to their capacity at recognizing complementary DNA and RNA sequences, α -L-threofuranosyl nucleoside triphosphates are well incorporated into TNA or DNA primers by modified and specifically engineered polymerases.^{185,215–218} The possibility of reverse transcribing DNA into TNA and then converting TNA into DNA using polymerases permits molecular evolution experiments to raise potent affinity reagents (aptamers) as well as TNA-based enzymes.^{219–224} The combination of chemical dissimilarity from the backbone of canonical nucleic acids with the propensity at adopting A-DNA conformations makes TNA an attractive analogue for the development of therapeutic oligonucleotides. What is more, TNAs are highly stable in human serum and acidic media, even more than RNA structural mimics such as 2'-F-RNA and FANA (see Section 2.3.3), which is an important prerequisite for therapeutic applications.^{225,226} Given these favorable assets, stability and high efficiency, siRNAs²²⁷ as well as antisense oligonucleotides^{223,228,229} have been constructed using TNA building blocks.

2.3.5 Xylonucleic acid. Xylose nucleic acids are based on the pentofuranosyl sugar D-xylose rather than ribose (Fig. 13).²³⁰ Both monosaccharides are distinguished by a seemingly simple inversion of configuration at position C3' and are thus epimers. In the early 1990s, Seela and colleagues first reported xylo-DNA (59 in Fig. 13 with R = H).²³¹ 2'-Deoxy-xylo nucleic acid homo-duplexes display T_m similar to that of parent DNA. However, they showed an inverted CD spectrum and possess higher stability towards endonuclease.²³² Otherwise, pairing with complementary DNA or inclusion of single xylose residues in DNA




Fig. 13 Chemical structures of five-membered xylose and pentulose phosphate derived nucleic acids.

sequences significantly destabilizes duplexes.^{232,233} Interestingly, even though xylose nucleic acids have a poor affinity for complementary DNA or RNA, they display a propensity for forming stable triple helices.^{234,235} Furthermore, Wengel and colleagues have synthesized several xylose-configured monomers and incorporated them in oligonucleotides.^{235,236} They observed that a single ribose replacement from a DNA/RNA with 2'-deoxyxylose or 2'-mono-substituted (59) or 2',4'-disubstituted (60, including LNA-like) xylose monomers or locked xylose monomers results in decreases in duplex stability.²³⁵ The poor cross-talk of xylose-containing sequences with canonical DNA and RNA is obviously detrimental to the development of therapeutics. However, they could potentially lead to the construction of alternative, orthogonal genetic systems provided efficient enzymes could be engineered to support their replication and synthesis.^{230,237,238}

2.3.6 Xylulo- and ribulonucleic acids. Other sugars such as L-ribulose and L-xylulose have also been investigated as alternatives to canonical (deoxy)ribose scaffolds. While ($1' \rightarrow 3'$)-connected α -L-ribulonucleic acids are synthetically highly demanding, building blocks of ($1' \rightarrow 3'$)- β -L-ribulo (61), ($4' \rightarrow 3'$), and ($1' \rightarrow 3'$)- α -L-xylulo (62 and 63 in Fig. 13, respectively) could be prepared and assembled into oligonucleotides by SPOS, mainly to address questions related to the etiology of the structure of nucleic acids.²³⁹ However, these sets of oligonucleotides were devoid of any self-pairing and cross-pairing capabilities with RNA.²⁴⁰ It has been observed that one or two insertions of xylulo nucleotides into RNA dramatically decrease the duplex formation capabilities of the modified RNA sequences.²⁴¹ Nucleic acid analogues based on the last representative of the pentose family, L-lyxose, have not yet been reported.

2.4 Six membered ring containing nucleic acids

As for xylulo- and ribulo-nucleic acids, expanding the ring size from five-carbon sugars (pentoses and pentuloses) to larger and



conformationally more rigid hexoses (mainly pyranoses) stems from efforts in understanding the chemical etiology of nucleic acids.^{15,16,239} In addition to these prebiotic considerations, sugar units with expanded size have attracted attention for the construction of alternative genetic polymers capable of storage of information due to their orthogonal base pairing capacities.⁵⁷ Also, the additional atom in the ring offers the possibility of introducing more substituents and hence gives rise to a larger number of isomers and analogues thereof. These monomers display different structural conformations which cannot be accessed by regular pentoses.¹⁹ Lastly, an important and interesting serendipitous finding stemming from the introduction of six-membered ring systems in nucleic acids is the concept of conformational restriction which allowed the potency of therapeutic oligonucleotides to be significantly improved.¹⁷

2.4.1 Hexopyranosyl nucleic acid. A fundamental question in nucleic acid etiology is why Nature chose pentoses rather than hexoses as key elements in the construction of nucleic acids.^{15,242} Clearly, pentoses and hexoses had at least equal chances to occur in a prebiotic world mainly *via* the formose reaction.²⁴³ Hence, the choice for one *versus* the other had to relate to functional, reactivity, and structural relevance rather than chemical synthesis.²⁴² In order to shed light onto this fundamental question, the group of Albert Eschenmoser initiated a vast program to synthesize nucleic acid analogues with six-membered sugar units.¹⁵

(4' → 6')-2,3-Dideoxy-*D*-glucopyranosyl nucleic acid (*homo*-DNA). The first system that was explored consisted of a single addition of a methylene unit on the pentose which resulted in oligonucleotides containing 4' → 6' connected 2',3'-dideoxy- β -*D*-glucopyranosyl nucleotides, the so-called β -homo-DNA (64 in Fig. 14).^{244,245}

β -Homo-DNA is not capable of recognizing single-stranded, complementary DNA or RNA sequences but forms antiparallel self-duplexes that are yet more stable than the corresponding canonical duplexes.²⁴⁶ This increase in thermal stability originates from a favorable entropic contribution itself stemming from the higher rigidity of six-membered hexoses. Interestingly, the preferences observed in canonical duplexes where G-C pairs are more stable than A-T pairs are not strictly obeyed in β -homo-DNA where base pairing follows the order: G-C > A-A ≈ G-G > A-T.²⁴⁶ Resolution of the crystal structure of a β -homo-DNA oligomer has revealed a ladder-like pairing conformation and a large backbone-base inclination along with a chair conformation of the sugar moiety.²⁴⁷




Fig. 14 Chemical structures of DNA and β -homo-DNA 64.




Fig. 15 Chemical structures of the most common hexitol-based nucleic acid analogues.

Subsequently, several hexopyranosyl-containing oligonucleotides, featuring (6' → 4')-allopyranosyl-, (6' → 4')-altropyranosyl-, (6' → 4')-mannopyranosyl- and (6' → 4')-glucopyranosyl-containing units were explored.²³⁹ Most analogues performed poorly at recognizing complementary sequences and the steric hindrance was especially severe in the (6' → 4')-glucopyranosyl system. In this system, the 2'- and 3'-OH moieties clash with the backbone as well as the edges of the bases which might explain why Nature's most abundant carbohydrate, *D*-glucose, is not preferred over *D*-ribose in genetic systems.²³⁹

Collectively, these results tend to suggest that Nature opted for a more flexible pentose rather than the rigid nature of six-membered sugars which imposes structural constraints. These in turn explain why oligonucleotides with six-membered sugar units cannot cross-talk with canonical DNA and RNA and display altered base pairing properties. Interestingly, by a simple change of the nucleobase from a β - to an α -orientation (64 in Fig. 15), partial communication to complementary RNA (but not DNA) could be restored.²⁴⁸

(6' → 4')-1',5'-Anhydro-*D*-arabino-hexitol nucleic acid (HNA). In the course of developing novel nucleoside antiviral agents, the group of Piet Herdewijn observed a good structural correlation between 2'-deoxynucleosides and 1,5-anhydrohexitol nucleosides which stem from a formal insertion of a methylene moiety between the carbon connecting the nucleobase to the sugar and the ring oxygen (66 in Fig. 15).²⁴⁹ Based on these considerations, the same laboratory expanded on these observations and incorporated 1',5'-anhydro-*D*-arabino-hexitol nucleosides into oligomers *via* 6' → 4' connections. The resulting HNA sequences form stable complexes with complementary DNA and RNA.²⁵⁰ Importantly, HNA displayed an important affinity for RNA (ΔT_m of ~ +3 °C per modification) due to the preferred conformation which is highly reminiscent of the C3'-*endo* sugar ring pucker found in canonical RNA.^{250–252} Substitution of single natural 2'-deoxynucleotides with the corresponding anhydrohexitol nucleotides led to duplexes with similar T_m values (ΔT_m of ~ +0.2 to –0.8 °C per modification) except for the dT to hT substitution which leads to a substantial decrease in melting



temperature (ΔT_m of ~ -2 °C). Interestingly, introducing a hydroxyl group at the 3'-position of the sugar (*D*-mannitol nucleic acids) decreases the stability of duplexes with complementary RNA and abrogates DNA recognition. This is due to the formation of strong hydrogen bonding interactions between the 3'-OH and 6'-oxygen of the phosphate backbone which causes a large deviation from the A-RNA like structure adopted by unmodified HNA.^{253,254} HNA has also been shown to display a propensity at forming duplexes with β -homo-DNA (64), suggesting that sequences containing different six-membered sugar units could cross-talk.^{20,255}

HNAs represent interesting scaffolds to improve the efficiency and properties of oligonucleotide therapeutics including antisense oligonucleotides,²⁵⁶ aptamers,^{67,257} and nucleic acid catalysts¹⁸⁶ but also to consolidate the architecture of nanotechnology objects.²⁵⁸ It is noteworthy mentioning that functional nucleic acids (*i.e.* binders and catalysts) obtained with HNA chemistry in the SELEX process require engineered polymerases that tolerate such an altered backbone.⁶⁷

D-Altritol nucleic acid (D-AlNA). The strong preference of HNA for complementary RNA over DNA is caused by a differential minor groove solvation.²⁵⁹ In order to improve the hydration of HNA/DNA duplexes, Herdewijn and colleagues prepared *D*-altritol nucleic acids (here we have used the abbreviation D-AlNA to avoid confusion with ANA 9 in Fig. 3 even though both structures often bear the same abbreviation) which is similar to HNA but bears an additional hydroxy moiety at position 3' of the sugar unit (11 in Fig. 3 and 15).²⁶⁰ While the introduction of such an additional hydroxyl moiety resulted in yet more stable complexes with RNA and DNA compared to those formed by HNA (66), the preference for DNA could not be increased. Interestingly, fully modified D-AlNA sequences form extremely stable homo-duplexes (ΔT_m of +10 °C per modification when compared to dsDNA). Unlike β -homo-DNA (64) which adopts near linear structures, both HNA (66) and D-AlNA (11) adopt A-form helical structures which explains not only their capacity at interacting with canonical nucleic acids but also their strong preference for RNA.^{260,261} As stated for HNA, D-AlNA is also a promising scaffold to improve the properties of oligonucleotide therapeutics²⁶² as well as functional nucleic acids.⁶⁷

D-Mannitol nucleic acid (D-MNA). A simple change in the stereochemistry of the carbon atom at position 3' from the (*S*)- in D-AlNA (11) to the (*R*)-configuration leads to *D*-mannitol nucleic acids (D-MNA, 67 in Fig. 15).²⁵³ This seemingly minute alteration has a profound impact on the molecular recognition capacity of the resulting oligonucleotides. Indeed, D-MNA oligonucleotides lose the capacity to interact with complementary RNA which is the exact opposite of its epimer D-AlNA (11). This differential behaviour was ascribed to unfavorable hydrogen bonding interactions and/or steric hinderance.

Cyclohexene nucleic acid (CeNA). Removal of the ring oxygen of the hexopyranosyl sugar of β -homo-DNA (64) not only results in a carbocyclic analogue but also in a chiral scaffold. The resulting cyclohexanyl nucleic acids (CNA) are capable of

strongly pairing to complementary RNA (ΔT_m of +1 °C per modification) and to a certain extent to DNA but only when in the *D*-isomer and not in the *L*-isomer configuration.²⁶³ However, CNA forms more stable self-complementary (*i.e.* CNA-CNA) than hetero-duplexes and thus displays a behavior that is intermediate between β -homo-DNA (64) and canonical nucleic acids, presumably due to the possibility of a chair flip of the cyclohexane moiety. The introduction of a double bond yields a cyclohexene sugar mimic which is yet more flexible than the cyclohexane in CNA and approaches the conformational flexibility of (deoxy)ribose. Cyclohexene nucleic acids (CeNA, 68 in Fig. 15) are better tolerated segments than CNAs within DNA than RNA sequences and lead to stabilization of duplexes formed with complementary RNA (ΔT_m of around +2 °C per modification).²⁶⁴ Importantly, unlike most hexopyranosyl nucleic acid analogues, DNA sequences containing CeNA (68) building blocks are capable of efficiently recruiting RNase H, which is an important feature for the development of antisense oligonucleotide therapeutics (besides the enhanced resistance against nucleases induced by the modified sugar backbone).²⁶⁵ Given the success of CeNAs, several cyclohexene nucleotide analogues containing fluorine or hydroxyl substituents have been prepared.^{266–268}

In terms of synthetic access, CNA and CeNA (68) containing oligonucleotides are mainly produced by SPOS even though an engineered polymerase supports enzymatic CeNA synthesis.⁶⁷

(6' → 4')- and (6' → 3')-Glucosamine nucleic acids (GANAs). *D*-Glucosamine is one of the most abundant monosaccharides. In contrast, examples of *D*-glucosamine-containing nucleic acids are scarce. Recently, Kitabe *et al.* reported the synthesis of (6' → 4')- and (6' → 3')-linked *D*-glucosamine nucleic acids that contain thymine in the anomeric position of the pyranose residue (69 and 70 in Fig. 16, respectively).²⁶⁹ Despite promising assets, the incorporation of zwitterionic glucosamine nucleotides at the 5'/3'-terminal positions or in the middle of a 15-mer DNA sequence led to the destabilization of DNA–DNA and DNA/RNA duplexes.²⁶⁹

2.4.2 Pentopyranosyl nucleic acid (p-RNA). Following the characterization of β -homo-DNA and related hexopyranosyl-containing systems, the Eschenmoser group investigated the possibility of converting RNA into the corresponding pyranosyl isomers. The first and most known analogue is (2' → 4')-connected β -D-ribopyranosyl-oligonucleotides, commonly known as p-RNA (10 in Fig. 3 and 17).^{270–273} As predicted by conformational analysis,²⁷⁰ Watson–Crick base pairing in p-RNA is




Fig. 16 Structures of glucosaminonucleic acids (GANAs) and comparison with β -homo-DNA (64).




Fig. 17 Chemical structures of p-RNA (10) and other representative members of the pentopyranosyl nucleic acid family (colour coding indicates differences in stereochemistry).

stronger (ΔT_m of +2 to +4 °C per modification¹⁷) and more selective than in canonical DNA or RNA duplexes.²⁷¹ Unlike hexopyranosyl nucleic acids, p-RNA strictly obeys antiparallel Watson–Crick base pairing rules and no alternative binding mode (e.g. Hoogsteen or self-pairing) has been observed. Structural and biochemical investigations have revealed that both β -homo-DNA (64) and p-RNA (10) adopt ladder-like, near linear conformations with large backbone inclinations but of opposite signs.^{272,274} Interestingly, short p-RNA oligomers can be assembled by template-independent ligation.^{271,275}

The Eschenmoser lab has also investigated other members of the (2' → 4')-connected pyranosyl nucleic acids (71) and all maintain strong base pairing capacities but none of these analogues can interact with canonical RNA. The strongest base pairing capacity, not only in this family but in general for all types of nucleic acids, has been observed in the α -arabinopyranosyl system.²⁷⁶

(3' → 4')-α-L-Lyxopyranosyl nucleic acid. The aforementioned (2' → 4')-connected pyranosyl nucleic acid (71) displays the same number of bonds per backbone unit as canonical DNA and RNA. Changing the connectivity from 2' → 4' to 3' → 4' will reduce the number of bonds from six to five and hence affect recognition of complementary sequences. In this context, the Eschenmoser laboratory reported α -L-lyxopyranosyl-(3' → 4') nucleic acid (72).²⁷⁷ Interestingly, this pyranosyl nucleic acid analogue with a shorter backbone unit displayed a propensity to form weak interactions with canonical DNA. In addition, α -L-lyxopyranosyl-(3' → 4') nucleic acids (72) formed weakly stable homo-duplexes and exhibited a capacity to form triplex structures. This is in stark contrast with other 3' → 4' connected ribopyranosyl oligonucleotide analogues such as β -D-ribopyranosyl nucleic acid (10), which do not form any stable complexes.

2.4.3 Phosphorodiamidate morpholino oligonucleotides. The replacement of the five-membered furanose with a six-membered morpholine ring leads to the formation of phosphorodiamidate morpholino oligonucleotides (PMO, 5 in Fig. 2).²⁷⁸ Due to their charge-neutral nature, PMOs form highly stable duplexes with complementary RNA sequences²⁷⁹ as well as triplexes.^{280,281} In addition to thermal stabilization of duplexes and triplexes, PMOs also massively enhance the stability of oligonucleotides in biological media,²⁸² but do not elicit RNase H.²⁸³ Given these highly favorable assets, PMOs are popular modification patterns in therapeutic oligonucleotides which is underscored by the FDA approval of several (*i.e.* four) ASOs for the treatment of Duchenne muscular dystrophy based on this

modification.²⁸⁴ Morpholino oligomers are mainly assembled by solid-phase synthesis and this access has recently been improved by the development of a streamlined protocol.²⁸⁵ Interestingly, PMOs are administered as racemic mixtures (due to the introduction of a chiral center on phosphorous) and no method has been devised yet, unlike PS linkages,²⁸⁶ to yield stereopure oligomers. Similarly, even though PMOs are major players in the field of therapeutic oligonucleotides and were developed decades ago, structural data on duplexes are scarce.²⁸⁷ Recently, thiomorpholino oligonucleotides (TMOs) have been proposed as alternatives to PMOs.²⁸⁸ TMOs contain a PS linkage instead of the *N,N*-dimethylamino moiety of PMOs. ASOs containing TMO units display increased exon skipping capacity and require lower doses than PMOs and oligonucleotides equipped with other modifications.²⁸⁹

2.5 Conformationally restricted nucleic acids

An important observation made with β -homo-DNA (64) is that the increased thermal stabilization of duplexes is of entropic rather than enthalpic origin. This decrease in entropy in turn stems from the decrease in flexibility of six-membered ring systems compared to the canonical five-membered (deoxy)ribose.^{244,290} In other words, the ring system in single stranded β -homo-DNA is already pre-organized in the conformation it adopts in duplexes which alleviates the entropic penalty associated with a change in structure upon binding. Conceptually, this feature can be hijacked to improve the efficiency of therapeutics, particularly of antisense oligonucleotides. Indeed, pre-organizing nucleic acid analogues in a conformation similar to that observed in duplex DNA, DNA–RNA, or RNA will yield thermodynamically more stable complexes. Efficient analogues obeying this strategy include bicyclo- (73) and tricyclo-DNA (74), LNA (75), CeNA (68) and HNA (66).

2.5.1 Bicyclo and tricyclo nucleic acids. The concept of reducing the torsional flexibility of the sugar phosphate backbone of nucleoside/nucleotide analogues was first reported by the group of Leumann with the so-called bicyclo-DNA (73 in Fig. 18).^{239,290–292} In bicyclo-DNA, the 5' and 3' centres are connected together with an ethylene bridge which concomitantly restricts the rotational freedom of the torsion angles δ and γ and locks the nucleoside in a conformation similar to that it adopts in duplex DNA (C1'-*exo*/C2'-*endo*).²⁹⁰ Fully modified bicyclo-DNA sequences with mixed base compositions form duplexes with complementary DNA and RNA of similar stabilities compared to that of natural systems.²⁹² These sequences can also form stable antiparallel homo-duplexes albeit of lower stability than DNA and RNA duplexes. Interestingly, Hoogsteen and reverse-Hoogsteen binding modes are preferred over Watson–Crick base pairing in homopurine bicyclo-DNA systems.^{291,293} This allows bicyclo-DNAs to form triplex structures.²⁹⁴

The introduction of bicyclo-DNA nucleotides (73) into oligonucleotide sequences generates a loss in enthalpy which is compensated by a decrease in entropy. In addition to favourable base pairing properties and enhanced nuclease resistance, the additional ethylene bridge allows for the introduction of substituents such as an amine²⁹⁶ or a fluorine atom.²⁹⁷ An interesting substitution pattern on bicyclo-DNA (73) is a cyclopropyl






Fig. 18 Chemical structures of bicyclo-DNA (73), tricyclo-DNA (74), and LNA (75) as well as their preferred conformations (adapted from ref. 17, 292 and 295).

ring between C5' and C6'. The resulting system, coined tricyclo-DNA (74 in Fig. 18), was conceived to further restrict the overall conformation of the nucleoside and correct the unfavourable geometry of torsion angle γ observed in bicyclo-DNA (C2'-*exo* sugar pucker).^{298–300} Fully modified tricyclo-DNA (74) sequences display remarkable binding properties since they form very stable duplexes with complementary DNA (ΔT_m of +1.2 °C per modification) and even more so with complementary RNA (ΔT_m of +2.4 °C per modification).³⁰¹ As a result, tricyclo-DNA (74) has been used extensively to improve the properties of therapeutics, particularly of exon-skipping antisense oligonucleotides which resulted successful in mouse testing.^{302,303} Various substituted versions of the tricyclo-DNA have then been reported to improve properties such as cellular delivery³⁰⁴ and recruiting of RNase H.³⁰⁵

Given the chemical nature of bicyclo- and tricyclo-DNA, polymerases do not readily incorporate the corresponding nucleotides into DNA and hence synthesis of sequences containing such modifications proceeds only *via* SPOS.^{306,307}

2.5.2 Locked nucleic acid (LNA). Another prominent member of the family of conformationally restricted nucleic acids are LNAs.³⁰⁸ LNAs are 2'-4'-bicyclic nucleic acids that were simultaneously co-developed by T. Imanishi *et al.*³⁰⁹ and J. Wengel *et al.*³¹⁰ (75 in Fig. 18). The nature of these fused rings constrains the flexibility of the nucleotidic scaffold, stabilising the sugar into a 3'-*endo* conformation. Locked nucleotides incorporated into oligonucleotides strongly improve the stability of duplexes with complementary DNA sequences (ΔT_m of +2 to +5 °C per modification).^{309,311} Since these nucleotides are locked in a 3'-*endo* conformation the affinity for RNA targets is yet more important than for complementary DNA (ΔT_m of +4 to +10 °C per modification).^{309,311}

Impressively, LNA-LNA duplexes as short as 9-mers display staggering thermal stabilities with T_m values exceeding 90 °C (*i.e.* ΔT_m > +60 °C compared to similar DNA–DNA duplexes).³¹² Given these impressive properties, LNAs (75) have advanced as important elements in numerous applications. For instance, LNA can improve the properties of therapeutic oligonucleotides such as gapmers^{174,313,314} and siRNAs.^{315,316} More recently, LNAs have been applied to CRISPR RNAs, where it was found that they were able to enhance Cas9 endonuclease specificity,

compared to unmodified RNA controls.³¹⁷ Locked nucleotides are also compatible with enzymatic synthesis,^{318–322} particularly with engineered polymerases, which enables their use in SELEX to identify aptamers⁶⁷ or for biotechnological applications.³²³

Although the increased binding provided by the inclusion of locked nucleotides is usually highly advantageous, if duplex hybridisation becomes too high, it can cause non-specific binding effects. As a result, LNAs (75) must be designed specifically to balance thermodynamic properties allowing for selective targeting while preventing toxic off-target effects.^{324,325}

2.6 Seven membered ring containing nucleic acids

Increasing the size of the sugar from five to six (Section 2.4) abrogated the capacity of nucleic acids to interact with canonical nucleic acids due to the decreased flexibility of pyranose compared to furanose. Expanding the sugar moiety to seven membered rings was expected to restore flexibility and hence cross-talk with canonical nucleic acids.³²⁶ Indeed, molecular modeling of oxepane nucleic acids (ONAs, Fig. 19) revealed that these analogues would adopt a more compact and slightly twisted chair conformation that would be compatible with complementary DNA and even more with RNA.³²⁶

However, once incorporated into homopurine and homo-pyrimidine sequences, (5' → 7')-connected ONAs (12) did not show any capacity at interacting with complementary DNA and only weakly with RNA.³²⁶ In order to improve the molecular recognition capacity of seven membered ring analogues for complementary DNA/RNA, additional hydroxyl groups were included in the scaffold and the connectivity was altered.^{56,327} The resulting oxepane derivatives were incorporated into DNA and RNA strands by SPOS.⁵⁶ Biophysical studies revealed that oxepane-modified RNA and DNA sequences (76) could cross-pair with complementary DNA and RNA, respectively. Nonetheless, single incorporation of OxNA into RNA sequences massively reduced their affinity for complementary DNA and RNA (ΔT_m > -10 °C per modification). On the other hand, when introduced into DNA sequences, only moderate (ΔT_m of ~ -4 °C per modification) or no destabilization was observed for (4' → 7')- (77) and (3' → 7')- (78) OxNA with complementary DNA and RNA, respectively. (5' → 7')-OxNA (76) was strongly destabilizing also in a DNA sequence context. The conformation analysis of these seven membered nucleoside analogues showed that the heptose unit adopts a chair conformation with the pyrimidine base in the equatorial position. While there are some structural differences between oxepane nucleic acids and (deoxy)-ribose oligonucleotides, molecular modelling and dynamics studies revealed that base–base stacking and sugar–phosphate H-bond




Fig. 19 Chemical structures of seven membered ring derived nucleic acids.



interactions are responsible for the tolerance of OxNA in DNA–RNA duplexes.

3. Nucleic acids containing glycosylated nucleobases

In addition to the canonical nucleobases that make up genomic DNA and RNA, naturally occurring variations of these canonical nucleobases affect the biophysical, biological, and chemical properties of nucleic acids. Until now, it has not been demonstrated that natural (epigenetic) modifications can change the specificity of Watson–Crick base pairing or reverse to another binding mode. In contrast, they were shown to affect gene expression, regulate a broad range of different biological pathways, and permit the interaction with cellular and viral encoded proteins.^{1–5,328} Advances in analytical tools and methodologies have enabled the genome-wide mapping of these modified bases and led to the discovery that naturally occurring carbohydrates were covalently attached to the pyrimidine or purine bases, particularly in the genome of phages.^{329,330} Glycosylation of proteins and lipids is ubiquitous. It plays fundamental roles in most cellular functions and is involved in various diseases.³³¹ Until recently, only DNA of bacteriophages was believed to be part of the glycome, mainly to elude protective mechanisms of hosts.³³² Nonetheless, the constant identification of additional and more complex post-transcriptional chemical modifications in RNA combined with the recent discovery of glycosylated RNA⁴⁵ suggest that this initial assumption might be inaccurate. Indeed, more than 140 RNA modifications have been discovered and these structural motifs are present at a variety of positions on all four canonical nucleobases.³³³ It is assumed that all RNA species in cells of all living organisms contain modified RNA nucleosides and the largest fraction of them are present in tRNAs. The chemical diversity displayed by epigenetic modifications ranges from small alterations such as methylation patterns to complete remodeling of the nucleobases (Fig. 20). One of the most common and ubiquitous modifications is pseudouridine (79, Ψ) which is present in all forms of RNAs and is often considered the fifth RNA base.³³⁴ More complex modifications are found on the so-called hyper-modified nucleobases. Two interesting representatives of the above are queuosine (81, Q)^{6,335} and wybutosine (80, yW).^{336–338}

The basic structure of the Q base features the central N7-deazaguanosine heterocycle bearing a carbon atom instead of a nitrogen in position 7 and a cyclopentenediol moiety attached *via* a methylamine moiety to the C7-position. Queuosine (81) is mainly found in tRNAs of bacteria and eukaryotes where it helps regulate translation and decode fidelity.^{339,340} In addition to these roles, the cyclopentenediol moiety of the Q base can be glycosylated in higher vertebrates with sugars such as D-galactose (Gal) and D-mannose (Man) to form the corresponding D-galactosyl-Q (82, galQ) and D-mannosyl-Q (83, manQ) hypermodified bases. The exact structures of manQ and galQ bases have recently been elucidated by the Carell group and revealed that the sugar is attached *via* β -glycosidic and




Fig. 20 Chemical structures of hypermodified nucleotides, including examples of glycosylation on the nucleobase.

α -glycosidic linkages in galQ (82) and manQ (83), respectively.^{6,8,339} Recently, the reaction mechanism of Q glycosylation was identified. It appears to involve RNA glycosylases and activated nucleotide diphosphate sugar precursors.³⁴¹ Despite extensive research over the last few years, the exact biological function of the Q base, and even more so of the corresponding glycosylated nucleobases galQ (82) and manQ (83), is still not fully known. It is believed though that Q may be important to preventing stop codon readthrough from occurring.^{341,342}

Besides galQ and manQ, no other hypermodified glycosylated nucleobases have yet been identified in RNA.³⁴³

However, the group of Bertozzi has reported in a groundbreaking study that RNA can be glycosylated with a variety of glycans.⁴⁵ This study found that small (<200 nt) noncoding RNAs contain covalently linked sialylated glycans which were dubbed as 'glycoRNAs'. Besides, sialic acid, fucose was identified to a certain extent. The exact chemical nature of these glycans as well as the structure of the linker and modified base have not yet been elucidated but the biosynthesis of glycoRNAs is unlikely to involve a direct glycosylation of RNA. Nonetheless, the sensitivity of glycoRNAs to treatment with amidase PNGase F which strips N-linked oligosaccharides off from glycoproteins suggests the presence of an amide bond between glycans and RNA. In this context, a recent study by Flynn and colleagues suggested that the modified RNA nucleobase 3-(3-amino-3-carboxypropyl)uridine (acp3U) acts as a connector between RNA and N-glycans *via* a carboxamide bond that would be generated on acp3U prior to conjugation to glycans (Fig. 21).³⁴⁴

Interestingly, most glycoRNAs are located at the cell surface, which raises important questions on their function, the mechanisms that permit trafficking of these glycoconjugates to this cellular location, and on how glycoRNAs are inserted into membranes. While these questions remain unanswered, a recent study revealed that in a mice model, cell surface glycoRNAs are involved in neutrophil recruitment to accelerate the






Fig. 21 Representation of glycoRNAs and connection to acp3U.

response to a tissue injury.³⁴⁵ More generally, glycans appear to assume multiple roles including protection of RNA against degradation and mediating binding to the lectin Selp which is important for neutrophil–endothelial interactions.

Ultimately, the expression of glycoRNAs on the cell surface indicates their significant biological importance, and further research will continue to uncover the many unknowns surrounding their function and structure.

3.1 O-Glycosylated nucleobases in DNA: hypermodified deoxycytidine

The chemical diversity of epigenetic modifications is much larger for RNA (>160) than in DNA (17, *vide supra*), which is possibly due to their highly complex and diverse functions. Despite this discrepancy, several glycosylated nucleobases have been identified in DNA. The most common epigenetic DNA modifications (Fig. 22) are the deoxycytidine analogues 5-methyl-dC (5mC, 84), 5-hydroxymethyl-dC (5hmC, 85), 5-formylcytosine (5fC, 86), and 5-carboxylcytosine (5caC, 87) along with the deoxyuridine derivative 5-hydroxymethyluracil (5hmU). Unsurprisingly, glycosylation of DNA often involves a sugar-attachment to one of the side chains of these common modification patterns. In this context, glycerol is the simplest carbohydrate that was found attached to a nucleobase. Indeed, 5-glycerol-methylcytosine (5gmC, 88) was detected in the genome of the green algae of *Chlamydomonas reinhardtii*.³⁴⁶ This modification is believed to act as a transcription repressor. It emanates from the addition of a glycerol unit to the exocyclic methyl group of 5mC (84) catalyzed by an analogue of the TET enzyme with vitamin C as a co-factor. Similarly, several hypermodified analogues of 5hmC (85) have been identified mainly in the genome of phages (89–91 in Fig. 22).³⁴⁷ The attached sugars consist mainly of D-glucose,^{332,348–350} but arabinosylation of 5hmC has also been reported.³⁵¹ Going beyond monosaccharide modifications, a small fraction of the 5hmC sites of the DNA of coliphages T2 and T6 has been found to be further modified with disaccharides, mainly β -linked diglucose units (gentiobiosyl, 91).^{352,353}

3.2 O-Glycosylated nucleobases in DNA: hypermodified deoxyuracil

β -D-Glucopyranosyloxymethyluracil (base J, 92 in Fig. 22) was the first discovered hypermethylated DNA nucleobase. It was




Fig. 22 Chemical structures of epigenetic DNA modifications (84–87) and carbohydrate modified nucleotides in DNA (89–93) and of the natural product septacidin (94). 5hmC (85): 5-hydroxymethyl-deoxycytidine; 5fC (86): 5-formyl-deoxycytidine; 5caC (87): 5-carboxy-deoxycytidine; 5gmC (88): 5-glycerol-methyldeoxycytidine; α/β -D-Glc-5hmC (89): α/β -D-glucosyl-5-(hydroxymethyl)deoxycytidine; 5hmU: 5-(hydroxymethyl)-uracil; β -D-Glc-5hmU (92): β -D-glucosyl-5-(hydroxymethyl)uracil.

detected in telomeres of trypanosomatids.^{354–356} Since its first discovery, base J has been identified in many other parasites where it acts as a terminator of transcription by regulating RNA polymerase II.^{357–359}

More complex hypermodification patterns have been identified in rare occasions. For instance, the DNA of bacteriophage SP-15 has been shown to contain deoxyuridine nucleotides modified with a 4,5-dihydroxypentyl moiety attached at position C5 of the nucleobase (5dhpU, 93). What is more, each of the hydroxyl groups of this linker were further modified with a glucuronolactone connected through a phosphodiester bond and a glucose residue (93 in Fig. 22). The exact connectivity of both hydroxyl units to each of these modifications has not yet been elucidated.^{360,361} Hocek *et al.* recently reported the enzymatic synthesis of DNA containing glucosylated uridine and cytidine nucleotides. The presence of the modified residues protects DNA against the activity of type II restriction endonucleases (Res). Their capacity at serving as templates in transcription by the RNA polymerase of *E. coli* depends on the nature of the nucleobase to which they are connected.³⁶² Indeed, glucosylated 5hmU units completely inhibited transcription while similarly modified 5hmC did not block RNA synthesis. Recently, this

approach was extended to nucleotides equipped with other carbohydrates.³⁶³

3.3 Glycosylated bacterial nucleosides

An interesting family of compounds are the septacidins (**94** in Fig. 22). These natural products consist of 1-heptosamine moieties which are decorated with a nucleobase, an amino acid residue, and a lipid, thus combining elements of all naturally existing biopolymers.^{364–366} While such nucleoside analogues have not yet been incorporated into nucleic acids, they display potent antibiotic and anticancer activities.

4. Carbohydrate–nucleic acid conjugates for efficient cellular delivery

Since the discovery of RNA interference (RNAi) by Fire and Mello,³⁶⁷ followed by a seminal clinical trial that demonstrated that siRNAs could specifically target human genes,³⁶⁸ there has been an exponential increase in interest in the synthesis of efficient and biostable siRNAs.^{37,39} These short RNA duplexes display several advantages compared to traditional drugs such as monoclonal antibodies or small molecules. Indeed, siRNAs recognize their mRNA target *via* Watson–Crick base pairing and do not need to specifically identify target proteins by binding to intricate three-dimensional folds. Also, siRNAs can be administered only a few times a year at most and are easier to prepare and store than antibodies for instance.^{369–371}

Even though the clinical success of siRNA-based therapeutics has been less than satisfactory, 22 different nucleic acid therapeutics have been approved by the FDA. Included are 6 siRNAs and 11 ASOs, while many more are in different stages of clinical trials.³⁷² Nucleic acid drugs and RNAs particularly have several limitations that are in part connected to their rather high molecular weight and the high density of negative charge on the phosphate backbone which massively restrict efficient cellular uptake of naked oligonucleotides. In addition, as mentioned previously, all nucleic acids are rather unstable in the presence of nucleases and can display undesired off target effects and *in vivo* toxicity. The low cellular uptake is caused by a repulsion of the phosphodiester backbone of oligonucleotides and the negatively charged lipids and (glyco)proteins on cell membranes.³⁷³ To overcome the challenges of delivering oligonucleotides to their intended cellular targets, various chemical strategies have been designed. A very popular strategy consists in attaching small peptides (<40 amino acids), coined cell-penetrating peptides (CPPs), to the termini of oligonucleotides. These CPPs are capable of penetrating cellular membranes, mainly by endocytosis, and hence will help attached oligonucleotides crossing these biological barriers.³⁷³ Similarly, lipophilic modifications such as fatty acids or cholesterol, are capable of interacting with the phospholipid bilayers of cellular membranes and when attached to oligonucleotides promote their internalization.^{374,375} Attachment of such modifications can be covalent and permanent or bioreversible.³⁷⁶ In this

context, carbohydrate–oligonucleotide conjugates have also been shown to improve cell-specific delivery through receptor-mediated endocytosis. Indeed, the benefit brought by the appendage of carbohydrates, often designed in the form of clusters, is reflected by the FDA-approved siRNA drug inclisiran used for the treatment of hypercholesterolemia.^{39,377} Equipped with an essential trivalent *N*-acetyl-D-galactosamine ligand (D-GalNAc, *vide infra*) that is preferentially recognized by the asialoglycoprotein receptor (ASGPR), inclisiran is specifically and efficiently delivered to hepatic cells without the need for any other vector or agent. Altogether, important research activity has been dedicated to producing and identifying (non-)natural carbohydrates conjugated with therapeutic oligonucleotides to help cellular delivery *via* carbohydrate–cell surface protein interactions. While factors such as the nature and valence of the selected carbohydrate clusters, and that of the connecting linker attached to the oligonucleotide are crucial for improved cellular delivery, we only discuss the general properties of carbohydrate–oligonucleotide bioconjugates. We defer the interested reader to recent review articles dealing with more specific therapeutic or design-oriented aspects of such hybrid constructs.^{378–380}

4.1 Monosaccharide nucleic acid conjugates

Conjugation of nucleic acids with carbohydrates can be quite challenging. To overcome synthetic hurdles, several approaches have been developed.^{380,381} Most existing methods to facilitate the crafting of nucleic acid–carbohydrate conjugates rely on the use of modified phosphoramidite building blocks in SPOS. For this, monosaccharides (such as glucose, galactose, fucose) or disaccharides (such as lactose, cellobiose) can either be directly converted to an phosphoramidite or first connected to a linker moiety. Alternatively, carbohydrates can also be conjugated to oligonucleotides in solution using suitably modified precursors and well-established attachment reactions such as S_N2 , oxime bond formation, and CuAAC (copper catalyzed azide alkyne cycloaddition).^{36,381–385} On the other hand, while biocatalytic approaches are currently explored for the production of (modified) oligonucleotides,^{119,386–389} biocatalysts have been underexplored for the synthesis of nucleic acid–carbohydrate conjugates (*vide infra*). Interesting enzymatic bioconjugation methods that could be explored in this context could encompass using glycogen phosphorylases and phosphorylated glycans,³⁹⁰ glycosyltransferases,^{391,392} or polymerase-based approaches with carbohydrate triphosphates.³⁹³ In this section, we describe illustrative examples of oligonucleotides equipped with mono- or multi-valent saccharides consisting of a single type of carbohydrate.

Berzal-Herranz *et al.* reported the conjugation of a single glucose moiety at the 5'-end of the fully phosphorothioate-modified antisense oligonucleotide GEM 91 (registered as Trecovirsen) which targets the translation initiation site of the HIV gag mRNA.³⁹⁴ The presence of a single glucose moiety further protected the antisense oligonucleotide against nuclease-mediated degradation. Importantly, this modification improved the therapeutic index of the antisense drug since, in addition to avoiding degradation, a significant reduction of the innate immune



response and potent anti-HIV-1 activity were both observed.³⁹⁵ Yet, the attachment of a glucose unit did not increase the cellular delivery of GEM 91, but this is presumably due to the presence of a short connecting linker arm. Indeed, similar siRNA-carbohydrate conjugates albeit featuring longer connectors (15–18 atoms) displayed enhanced cell penetration capacities.³⁸² Interestingly, a similar trend was observed when the glucose appendage was per-methylated, even though the cellular penetration capacity was reduced compared to unmodified glucose.³⁹⁶ The same authors then investigated the influence of the nature of the sugar moiety and the number of attached carbohydrates on the cellular uptake and capacity of siRNAs at regulating the expression of a target gene (Fig. 23).

Indeed, Eritja *et al.* synthesized siRNAs designed to inhibit the expression of the tumor necrosis factor (TNF- α) and modified with one to four glucose and galactose residues covalently linked to the 5'-end of the passenger strand.³⁸³ siRNAs equipped with galactose instead of glucose produced better gene silencing activities. D-Glucose-modified oligonucleotides did not display any significant capacity at penetrating the membrane of HeLa cells. siRNAs decorated with galactose units could enter HuH-7 cells, albeit with moderate efficiency, most likely *via* interaction with ASGPRs. The number of ligands appended to the siRNAs did not appear to influence the outcome of all these experiments.

Macrophages represent one of the major producers of the cytokine TNF- α and hence perform numerous and essential immune reactions under various pathophysiological conditions. Due to their biological relevance and involvement in several pathologies, macrophages have advanced as alluring therapeutic targets. Particularly, macrophages can be coerced to produce TNF- α by stimulating some Toll-like receptors (TLR) such as TLR-9. In this context, oligonucleotides that contain CpG motifs (CpG ODN) are good TLR-9 ligands and upon binding can elicit the production of significant amounts of cytokines like TNF- α , IL-6, and IFN- γ . In order to improve cellular delivery, CpG ODNs can be directly conjugated with

D-mannosyl residues which can interact with the D-mannose receptor CD 206 mainly found on macrophages.³⁹⁷ Such a simple construct improved the cellular delivery two-fold compared to the unmodified counterparts. Moreover, the presence of D-mannose did not interfere with TNF- α release. A similar strategy was employed for the targeted delivery of siRNAs and silencing of the hypoxanthine phosphoribosyl transferase 1 and beta-2 microglobulin genes.³⁹⁸ The cellular uptake of the siRNA-carbohydrate conjugates was strongly improved by using tetra- instead of monovalent D-mannose ligands due to strong (K_D value of 2.9 nM) and specific binding to the CD 206 receptor. The presence of four rather than one D-mannose moieties also improved gene silencing activity due to preferential internalization mediated by the former. The number of D-mannoses that are strictly required for efficient cellular delivery is still a matter of debate. Notably, a trivalent cluster was found to be sufficient for efficient cellular delivery and gene silencing activity both *in vitro* and *in vivo*.³⁹⁹ On the other hand, while increasing the valency to six D-mannose units further improved receptor binding and internalization efficiency, the presence of octavalent D-mannose complexes appeared to be slightly detrimental.⁴⁰⁰

Collectively, these observations clearly showcase the complex interplay between each constituting element of oligonucleotide-carbohydrate conjugates. The length of the linker arms as well as the number of and the nature of the sugar moieties can all have a profound impact on the biological properties and functions of such conjugates. These studies also demonstrate the possibility of site-specific delivery of therapeutic oligonucleotides by using sugar-receptor interactions. This concept was further developed and resulted in one of the major discoveries in the field of therapeutic oligonucleotide delivery in the last decades: triantennary N-acetyl-D-galactosamine (D-GalNAc) conjugation at the 3'-terminus of a preferred nucleic acid segment (Fig. 24).³⁶

Liver cells (hepatocytes) assume multiple essential functions including converting metabolites such as carbohydrates into energy, metabolizing toxic agents, or removing aging proteins and cells from the blood stream.³⁷⁸ They use multiple glycan-specific surface receptors to distinguish glycoproteins that need to be degraded from those which should be left intact. One of the most expressed receptors on the surface of hepatocytes




Fig. 23 Representative examples of monovalent, tetravalent, and hexavalent carbohydrate-siRNA conjugates.




Fig. 24 Chemical structures of a triantennary D-GalNAc ligand and examples of metabolically stable glycosidic linkages incorporated in siRNAs.



(100 000 to 500 000 per cell⁴⁰¹) is ASGPR.⁴⁰² The C-type lectin ASGPR is specific for the terminal galactose of glycoproteins and recognizes preferentially D-GalNAc (K_D value of 2.5 nM) over D-Gal or D-Gal-like moieties such as D-fucose or D-lactose.^{401,403-405} Early studies have also demonstrated that monovalent sugars display low binding affinity for ASGPR and multivalent ligands are necessary for potent recognition.^{403,404} Based on these considerations, Manoharan and colleagues equipped the 3'-termini of the sense strand of siRNAs with bi- and tri-antennary D-GalNAc ligands.³⁶ Trivalent D-GalNAc systems were much more efficient at cellular delivery of siRNAs³⁶ and antisense⁴⁰⁶ oligonucleotides than the corresponding biantennary ligands. In addition, since binding of a D-GalNAc to ASGPR is pH-dependent (due to release of the required Ca^{2+} cofactor which ensures binding to the glycan),^{21,406} the D-GalNAc-siRNA conjugate dissociates from ASGPR in the endosome.⁴⁰⁷ Upon internalization into hepatic cells, the D-GalNAc-oligonucleotide conjugates are further metabolized, mainly by glycosidases, at various sites including the glycosidic and amide bonds of the D-GalNAc cluster as well as the connecting phosphodiester linkage.⁴⁰⁸ This enzymatic degradation eventually liberates the therapeutic oligonucleotide. Interestingly, when the glycosidic bonds of D-GalNAc ligands were stabilized by replacing the anomeric C-O linkages with C-S, C-N, or C-C bonds (Fig. 24), the metabolic stability of the resulting carbohydrates clusters was improved without affecting ASGPR-binding.⁴⁰⁹ Besides increasing the biostability of the triantennary D-GalNAc ligand, this study also revealed that the stereochemistry and the nature of the glycosidic bonds are not crucial for specific and strong interaction with ASGPR. On the other hand, increasing the metabolic stability of the D-GalNAc delivery system did not correlate with improved duration of gene silencing activity suggesting that this is governed by the intrinsic stability of siRNAs rather than by that of the ligand. Building on decades of research, Alnylam pharmaceuticals conjugated a trimer of D-GalNAc to several siRNAs that were driven through clinical trials. Subsequently, several of these D-GalNAc-conjugated siRNAs, including givosiran, lumasiran, inclisiran, and vutrisiran, have been approved for clinical use by the FDA.³⁹

Besides siRNAs, D-GalNAc conjugation has been employed for the successful delivery to hepatocytes of antisense agents,^{408,410} miRNAs,⁴¹¹ anti-miRNAs,⁴¹² and D-GalNAc-lipid nanoparticles for CRISPR base editing therapy.⁴¹³

4.2 Disaccharide/oligosaccharide–nucleic acid conjugates

Besides monosaccharides or polysaccharides consisting of repeats of the same carbohydrate unit, more complex oligosaccharide systems begin to be investigated as potential delivery systems for therapeutic oligonucleotides.

An interesting example stems from the glycopeptide-derived antibiotic bleomycin (BLM) which is used for cancer treatment. The therapeutic activity of BLM stems from its capacity at inducing damage to both ssDNA and dsDNA when in the presence of defined cofactors (*i.e.* Fe^{2+} and O_2). BLM consists of several key elements, notably a six amino acid peptide chelator of Fe^{2+} (for the DNA cleavage activity), a bithiazole tail

which is involved in DNA intercalation, and a disaccharide moiety which is responsible for tumor cell selectivity.⁴¹⁴⁻⁴¹⁶ The 2-O-(3-carbamoyl- α -D-mannopyranosyl)-L-gulose disaccharide motif of BLM can thus represent a potential tool for the specific delivery of therapeutic oligonucleotides to cancer cells. In this context, trimers of the BLM disaccharide were conjugated with splice-switching antisense oligonucleotides (Fig. 25). These glycoconjugates were then assembled together on spherical nucleic acids (SNAs) by Watson–Crick base-pairing with a complementary sequence present on the SNA surface. The resulting carbohydrate-decorated spherical nucleic acids were taken up by the prostate cancer cell line PC3 more efficiently than the corresponding carbohydrate–oligonucleotide conjugates.⁴¹⁷

Sialic acid-carrying ligands represent another interesting example of oligosaccharide-based systems used to enhance the pharmacokinetics of therapeutic oligonucleotides. Indeed, the CD22 receptor (Siglec 2) which is highly expressed on B-cells and B cell lymphomas, modulates B-cell signalling. The inhibitory activity of CD22 is regulated by an extracellular ligand-binding domain which exclusively recognizes sialylated carbohydrates, mainly the sequence Neu5Ac α -2-6Gal β 1-4GlcNAc.⁴¹⁸ The appendage of trimers of this trisaccharide to the 3'-end of the sense strand of an siRNA targeting hypoxanthine phosphoribosyl transferase 1, resulted in strong binding of the conjugates to CD22 receptors (K_D values in the low nM range). After binding to CD22, the glycosylated siRNAs were efficiently internalized into cells *via* endocytosis and the modifications did not preclude gene knockdown of Hprt-1.⁴¹⁹ Even though further optimization of the ligand structure and valency will be necessary to improve the knockdown activity, this study clearly highlights the potential of using sialylated-nucleic acids to promote cellular delivery *via* binding to CD22. It is noteworthy mentioning that the chemical integrity of the oligosaccharide is of high importance since small changes in composition can be deleterious to cellular internalization.⁴²⁰




Fig. 25 Chemical structures of representative examples of disaccharide/oligosaccharide–nucleic acid conjugates.



Besides delivery systems, the binding affinity of oligosaccharides such as oligomannose (Man_9) glycans can be raised from low (K_D of μM to mM range) to high (K_D in the low nM range) by combining grafting on oligonucleotides and *in vitro* evolution methods.^{421,422}

5. Future perspectives and applications

Chemical modifications of nucleic acids have been used to elucidate, manipulate, and stabilize non-canonical structures and ultimately have permitted the intrusion of oligonucleotides into a plethora of applications. Importantly, the introduction of modified nucleoside analogues has also been crucial for the development of potent oligonucleotide therapeutics, including antisense, RNAi, and aptamer-based candidates, without which the field would not have gained such important momentum. Carbohydrate-based modifications slowly infiltrate the field of nucleic acids. At first, modifications were targeted at the constituting sugar moiety of the (deoxy)ribose scaffold. With the advent of glycoRNAs and d-GalNAc-based delivery agents, more complex carbohydrate modifications introduced at multiple locations of the scaffold are being considered such as oligomannose or bleomycin-based systems. This trend will undoubtedly continue and in this section, we summarize other existing applications of carbohydrates in the field of nucleic acids and highlight possible future directions in production and development of such constructs.

5.1 Stabilization of structural motifs

5.1.1 Stabilization of G-quadruplexes. G-quadruplexes are structures that consist of stacked guanine tetrads stabilized by Hoogsteen base pairs and central monovalent cations (Na^+ or K^+). The number of strands and the topology of a G-quadruplex can vary depending on several factors, such as loop length and composition, the nature of the stabilizing cation, and nucleotide orientation.^{423,424}

Modified nucleosides, particularly guanosine analogues, can be strategically placed to stabilize and modulate the folding topology of G-quadruplexes. Small sugar-modified guanosine analogues such as FANA (2'-F-araG, 58) and LNA (LNA-G, 75) have been introduced in G-quadruplex structures.^{425,426} Generally speaking, when introduced in *anti* positions, such modified nucleotides stabilize G-quadruplexes while substitution in *syn* positions is often detrimental.⁴²⁷ The use of 2'-F-araG has also proven beneficial in studying telomerase activity by inducing an exclusive and stable parallel topology in the otherwise polymorphic telomeric G-quadruplex, as demonstrated by single-molecule FRET studies.⁴²⁸ Interestingly, TNA (8) can also adopt G-quadruplex structures of similar stability and structure to those formed by canonical DNA and RNA, except that both Na^+ or K^+ are equally well tolerated.⁴²⁹ While more complex sugar modified residues such as those involved in β -homo-DNA (64) or 5'-7'-ONA (12) have not been introduced in G-quadruplexes yet, the recent identification and characterization of an HNA (66) aptamer

suggests that this functional nucleic acid adopts stable G-quadruplex-like structures.⁴³⁰ In the near future, other more complex, mainly XNA analogues, will undoubtedly be explored for their capacity to form and/or stabilize such structures.

Finally, carbohydrates have been found to interact with and stabilize G-quadruplexes mainly *via* stacking, hydrogen bonding, and hydrophobic contacts.⁴³¹ These observations open up the possibility of using carbohydrate-G-quadruplex interactions to develop novel drugs,^{432,433} identify specific ligands,⁴³⁴ or modulate their structures. Ultimately, oligosaccharides such as d-GalNAc ligands could also be employed to facilitate the cellular delivery of functional nucleic acids adopting G-quadruplex structures.^{435,436}

5.1.2 Stabilization of intercalated-motifs. The intercalated motif (i-motif) is another non-B-DNA like structure reminiscent of G-quadruplexes.⁴³⁷ In an i-motif, hemi-protonated C-C⁺ base pairs stabilize an architecture consisting of four cytosine-rich DNA sequences that fold into antiparallel duplex ladders. Such i-motifs have recently been identified in human cells under physiological conditions.⁴³⁸ Still, their stability under pH 7 appears to be strongly dependent on their methylation pattern.⁴³⁹ Unmethylated or hypomethylated DNA do not form stable i-motif structures beyond acidic pH and this represents a challenge for their use in *in vitro* applications under physiological conditions. Various nucleoside modifications have been used to investigate the factors leading to poor stability of i-motifs at neutral pH⁴³⁹ and ways to stabilize such structural motifs beyond pH 5.5.^{440,441} In this context, some nucleobase-modified cytidine analogues have been shown to enhance the stability of i-motifs either *via* increased stacking interactions⁴⁴² or by introducing additional hydrogen bonding partners.⁴⁴³

Alternatively, this structural motif can also be stabilized by introducing sugar-modified cytidine analogues. However, this is not an easy undertaking since the nucleotides should be preorganized in a C3'-*endo* conformation which is favored for i-motif formation without including electronegative substituents at position 2' of the ribose since these are detrimental for this structural motif.^{37,444} Nonetheless, some stabilization of i-motifs could be achieved when ara-C (9), 2'-F-araC (58), and LNA-C (75) were introduced at specific locations.³⁷ Indeed, 2'-fluoro-ribonucleotides moderately stabilize i-motifs by reducing the solvation effect.^{445,446} LNA-C substitutions can have varying effects on i-motif stability depending on the number and their localization within the sequences.^{444,447} In particular, LNA-C nucleotides stabilize i-motifs at specific locations due to a favorable C3'-*endo* conformation and the formation of additional C-H \cdots O interactions that compensate for unfavorable van der Waals contacts.^{444,447} In contrast, araC and 2'-F-araC adopt both C2'-*endo* (South) conformations but still induce a degree of stabilization because their 2'-substituent points towards the major groove which thus avoids steric clashes.^{445,448} Of all nucleosides featuring a substituted sugar analogue, 2'-F-araC revealed to be the most effective at stabilizing i-motifs at neutral pH. Notably, an impressive ΔT_m of over 17 °C was observed for an i-motif containing four 2'-F-araC analogues instead of dC units.⁴⁴⁵ Interestingly, even though HNAs (66) display a favorable C3'-*endo*



conformation they do not seem to be capable of forming stable i-motifs.⁴⁴⁹

As mentioned in the section on G-quadruplexes, more stable i-motifs will undoubtedly be identified in the future by screening other (more complex) sugar modifications especially those stabilizing C3'-*endo* sugar pucksers such as variants of HNA (66), CeNA (68), and bicyclo- (73) or tricyclo- (74) DNA. Furthermore, the addition of carbohydrates on nucleobases or at terminal locations of sequences might also contribute to the overall stability of i-motifs.

5.2 Carbohydrate modifications in therapeutic oligonucleotides

Therapeutic nucleic acids have tremendously benefited from the introduction of modified sugar moieties and the appendage of oligosaccharide-based ligands to increase their therapeutic index. Indeed, many (deoxy)ribose modifications such as 2'-OMe (2), 2'-F (3), 2'-MOE (4), LNA (75), and FANA (58) are routine chemical alterations of oligonucleotides and drastically improve oligonucleotide nuclease stability and binding affinity to complementary RNA. Conjugation with carbohydrate ligands such as triantennary D-GalNAc, D-Man, or sialic acid-containing moieties permits efficient and specific cellular delivery of therapeutic nucleic acids without negatively impacting their biological function.

So far, mainly siRNAs and ASOs have benefited from such modification patterns, but lessons learned from these treatment modalities will certainly be applied to other purposes in the future. In this context, the first examples of modified CRISPR RNA (crRNA) sequences for CRISPR/Cas9 and Cas12 applications^{450,451} and RNA segments for endogenous adenosine deaminases acting on RNA (ADAR)-mediated RNA editing have already been reported.⁴⁵² Appendage of carbohydrates at the 5'-termini of triplex forming oligonucleotides could enhance the stability of triplets under physiological pH *via* stacking and van der Waals interactions which would be of importance for more efficient antigenic therapy.^{160,453} Finally, mRNA vaccines are relatively new players in the field of FDA-approved therapeutic nucleic acids and display a huge potential for vaccination and therapy.⁴⁵⁴ These agents will certainly benefit from sugar modifications and/or conjugation to carbohydrates. Specifically, mRNA vaccines could be encapsulated in polysaccharides rather than lipid nanoparticles or equipped with D-GalNAc ligands to facilitate their delivery and more importantly convey target specificity.

Lastly, all (therapeutic) oligonucleotides will benefit from the identification of additional and optimized receptor-ligand pairs to favor specific cellular delivery. These additional ligand systems would remediate one of the long-standing challenges in the field of therapeutic oligonucleotides: specific and efficient cellular delivery.

5.3 Alternative XNA-based functional nucleic acids

XNA building blocks have been included in SELEX experiments and related combinatorial methods of *in vitro* selection for the identification of aptamers and catalysts to improve their biological stability but also their functions.^{42,126,207,222,455} Initially,

nucleoside triphosphates equipped with small sugar alterations such as 2'-OMe (2), 2'-F (3), and 2'-NH₂ were used to construct naïve libraries for SELEX. Progress in protein engineering and directed evolution has led to the discovery of polymerases and reverse transcriptases capable of synthesizing XNA sequences from DNA templates and complementary DNA from XNAs.^{127,456,457} In turn, these more tolerant mutant enzymes have permitted the introduction of more complex sugar modifications such as TNA (8), HNA (66), or charge-neutral sugar backbones into SELEX protocols.^{206,224,458} This trend is expected to continue or even increase to include other alternative sugar modification patterns in functional nucleic acids. An interesting example consists of L-stereoisomer oligonucleotides or mirror-image DNA/RNA also coined Spiegelmers.⁴⁵⁹ These mirror image nucleic acids do not cross-talk with canonical D-oligonucleotides (but form Watson-Crick base pairs with complementary L-sequences) and are not recognized by natural enzymes including nucleases. L-aptamers and L-oligonucleotides thus display a remarkable biostability.⁴⁶⁰ However, since these analogues are not recognized by natural, L-amino acid containing enzymes, they cannot be copied or transcribed by existing polymerases or reverse transcriptases. Recently, a mirror-image version of the T7 RNA polymerase was produced and shown to be capable of *in vitro* transcription of short L-RNA sequences, thus opening up the possibility of direct *in vitro* selection of Spiegelmers.⁴⁶¹

5.4 Biocatalytic methods to produce carbohydrate-nucleic acid conjugates and sugar-modified sequences

Most sugar-modified oligonucleotides as well as all carbohydrate conjugates are mainly produced by SPOS. While this is a robust and versatile method that is clearly suitable for an immense diversity of modified phosphoramidites, the identification of more potent sugar modifications, ligands, or longer sequences would benefit from alternative synthetic protocols. For instance, an efficient version of SPOS but with suitable carbohydrate building blocks would certainly facilitate the production of oligosaccharides.^{462,463} In addition, alternative biocatalytic approaches would aid in the production of longer oligonucleotides containing modified sugar and/or nucleobases decorated with carbohydrates. Such approaches could involve polymerase-based methods,^{386,389,457,464} ligases,^{129,465} or nucleic acid enzymes.⁴⁶⁶ Lastly, glycosyltransferases and related enzymes could be used for the production of glycoRNAs to help understand their structures and biological functions.

6. Conclusions

Besides being an integral and central element of the structure of DNA and RNA, carbohydrates can be modified or added to the scaffold of nucleic acids to alter their physicochemical properties and biological functions. In the first part of this review article, we have described the most common (deoxy) ribose modifications of nucleotides that were introduced into oligonucleotides. Such synthetic campaigns were mainly undertaken to understand the etiology of nucleic acids, improve the



Table 1 Summary of most common therapeutically relevant sugar modifications










Chemical structure	Sugar pucker	Main properties	Selected references
	C3'-endo	Enhanced duplex stability (ΔT_m of +1 °C per modification) opposite RNA (<i>i.e.</i> increased target recognition), enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, no recruitment of RNase H and no enhanced delivery	39, 95, 101 and 104
	C3'-endo	Enhanced duplex stability (ΔT_m of +2–3 °C per modification) opposite RNA (<i>i.e.</i> increased target recognition), enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, no recruitment of RNase H and no enhanced delivery	39 and 94–96
	C3'-endo	Enhanced duplex stability (ΔT_m of +1–2 °C per modification) opposite RNA (<i>i.e.</i> increased target recognition), enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, no recruitment of RNase H and no enhanced delivery	39, 112, 117 and 118
	n.a.	Charge neutral, enhanced cellular delivery and nuclease resistance, stabilization of duplexes and triplets, do not elicit RNase H, common backbone modification in ASOs and siRNAs, four ASOs based on PMOs have been approved by the FDA, no structural information	287 and 467
Morpholino Oligomers (PMO)			
	C4'-exo	Stems from questions on the chemical etiology of nucleic acids. Capable of cross-pairing with DNA and RNA, but destabilize duplexes. Enhanced nuclease resistance, used in siRNAs, aptamers, and the design of XNAs	209, 210, 224, 227 and 468
	C2'-endo	Reduced duplex stability (ΔT_m of –1 to –1.5 °C per modification) opposite RNA, form triplets, enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, capacity of recruiting RNase H	181, 183 and 184
	O4'-endo	Enhanced duplex stability (ΔT_m of ~1 °C per modification) opposite RNA (<i>i.e.</i> increased target recognition), enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, capacity of recruiting RNase H; part of XNAs and used in aptamers and DNAzyme selections	67, 186, 193, 196, 198 and 199



Table 1 (continued)

Chemical structure	Sugar pucker	Main properties	Selected references
	C3'-endo	Enhanced duplex stability (ΔT_m of ~ 3 °C per modification) opposite RNA (<i>i.e.</i> increased target recognition), enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, no capacity to recruit RNase H; part of XNAs and used in aptamers and DNAzyme selections	67, 186, 250, 252 and 430
HNA, 66			
	C1'-exo/C2'-endo	Conformationally restricted nucleotide, slight stabilization of duplexes with complementary DNA and RNA, triplex formation, enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, has been introduced in exon skipping ASOs, some chemical variants of 73 can recruit RNase H ¹⁶⁹	292–294
bicyclo-DNA, 73			
	C2'-exo	Conformationally restricted nucleotide, enhanced duplex stability (ΔT_m of ~ 2 °C per modification) opposite RNA (<i>i.e.</i> increased target recognition), enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, has been introduced in exon skipping ASOs, some chemical variants of 74 can recruit RNase H	298, 299, 301 and 302
tricyclo-DNA, 74			
	C3'-endo	Conformationally restricted nucleotide, enhanced duplex stability (ΔT_m of ~ 4 –10 °C per modification) opposite RNA (<i>i.e.</i> increased target recognition) and DNA (ΔT_m of ~ 2 –5 °C per modification), enhanced nuclease resistance and chemical resistance to base, increased <i>in vivo</i> half-lives and stability in plasma, capacity to recruit RNase H, used in gapmers and siRNAs, and in XNA aptamers and catalysts	67, 186, 309, 310, 312, 313 and 315
LNA, 75			

properties of therapeutics, and develop synthetic and orthogonal genetic polymers. In the second part of this review article, we have described the most common carbohydrate–nucleic acid conjugates either naturally occurring or chemically designed on purpose. These hybrids are mainly employed in therapeutic applications to improve cellular delivery both in terms of specificity and efficiency. Lastly, we have provided insights into future potential developments of such modified nucleic acids and alternative methods for their production. This field has profited from interesting and vast chemistry programs aimed at developing nucleoside and nucleotide antiviral agents in the 1970s and 1980s and has now emerged as an increasingly important area of research. It is expected that the development of alternative sugar modifications, ligand–receptor systems based on carbohydrates, and synthetic protocols will yield potent FDA-approved drugs, robust binders and catalysts, and might shed more light into the origin of life.

7. Summary

7.1 Sugar modifications

Numerous synthetic campaigns were launched to identify sugar modifications that could help oligonucleotides resist against nuclease-mediated hydrolysis and thus increase their therapeutic usefulness. In addition, these synthetic efforts were guided by early research dedicated to identifying potent nucleoside

antiviral agents. This combination led to the development of three generations of chemical modifications commonly employed in oligonucleotides undergoing clinical trials and in the > 20 FDA-approved nucleic acid therapeutics.³⁹ The most common sugar modifications are summarized in Table 1, along with their most striking properties.

Other sugar modification patterns stem from questions related to chemical etiology of nucleic acids and the origin of life. For instance, structures such as β -homo-DNA (64) and p-RNA (10) have shed light onto Nature's choice for five rather than six-membered rings. Though not initially planned, studies towards the understanding of chemical etiology have also spawned interesting scaffolds for therapeutic applications *via* conformational restriction of nucleotides (highlighted in Table 1). In addition, given the inherent incapacity of certain surrogates to cross-talk with natural nucleic acids, these questions have also led to the development of XNAs. XNAs are sugar modified nucleic acids orthogonal to DNA/RNA that are capable of heredity and evolution. The most common XNA scaffolds are also highlighted in Table 1.

7.2 Glycosylated nucleobases

Glycosylated DNA nucleobases are found in the genome of bacteriophages and parasites and help elude immune defense responses during infection.⁴⁷⁰ The recent advent of glycosylated-RNA further underscores that nucleic acids are an integral part of the glycome on



Table 2 Summary of most common carbohydrate-based nucleobase modifications




Chemical structure	Main properties	Selected references
	Hypermodified, natural RNA modification mainly found in tRNAs, plays a role in preventing stop codon readthrough.	8, 339 and 341
	Hypermodified, natural RNA modification mainly found in tRNAs, exact biological role is not yet known.	339 and 342
	First hypermodified DNA nucleobase to be identified, terminates transcription, eludes defence mechanisms.	362 and 470



Table 2 (continued)

Chemical structure	Main properties	Selected references
<p>Septacidin 94</p>	L-Heptosamine containing a nucleobase, an amino acid residue, and a lipid; potent antiviral and anticancer activities.	364 and 365

par with proteins and lipids. The identification of novel glycosylation patterns and the understanding of the structure and biological function of glycan-bearing DNA and RNA are of high relevance and gaining increased attention. The most relevant glycosylated nucleobase patterns are summarized in Table 2.

7.3 Carbohydrate conjugates

In addition to modifying the nature of the deoxyribose/ribose of natural nucleic acids and adding glycans on the nucleobases, carbohydrates can be conjugated to the 5'/3'-termini of oligonucleotides. These appended carbohydrates guide therapeutic oligonucleotides to their target and favor their cellular delivery after receptor binding. Moreover, the addition of multiple rather than single carbohydrate units often enhances receptor recognition and specificity of oligonucleotides by the principle of multivalency. Carbohydrate-oligonucleotide conjugates are essential to improve the therapeutic index of nucleic acids. The most prominent member of this type of modification undoubtedly is the triantennary GalNAc ligand.

Data availability

No primary research results and no new data were generated or analysed in the context of this review article.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge generous funding from DARII and Institut Carnot 'Pasteur Microbes and Health' Call 2021 (grant # INNOV-100-21, including a postdoctoral fellowship to D. D.).

Notes and references

- 1 X. Chen, H. Xu, X. Shu and C.-X. Song, *Cell Death Differ.*, 2025, **32**, 56–65.
- 2 Y. Chen, T. Hong, S. Wang, J. Mo, T. Tian and X. Zhou, *Chem. Soc. Rev.*, 2017, **46**, 2844–2872.
- 3 J. Song and C. Yi, *ACS Chem. Biol.*, 2017, **12**, 316–325.
- 4 P. J. McCown, A. Ruszkowska, C. N. Kunkler, K. Breger, J. P. Hulewicz, M. C. Wang, N. A. Springer and J. A. Brown, *Wiley Interdiscip. Rev.: Mech. Dis.*, 2020, **11**, e1595.
- 5 F. Gracias, O. Ruiz-Larrabeiti, V. Vaňková Hausnerová, R. Pohl, B. Klepetářová, V. Sýkorová, L. Krásný and M. Hocek, *RSC Chem. Biol.*, 2022, **3**, 1069–1075.
- 6 A. Pichler, M. Hillmeier, M. Heiss, E. Peev, S. Xefteris, B. Steigenberger, I. Thoma, M. Müller, M. Borsò, A. Imhof and T. Carell, *J. Am. Chem. Soc.*, 2023, **145**, 25528–25532.
- 7 M. Witzenberger, S. Bureczyk, D. Settele, W. Mayer, L. M. Welp, M. Heiss, M. Wagner, T. Monecke, R. Janowski, T. Carell, H. Urlaub, S. M. Hauck, A. Voigt and D. Niessing, *Nucleic Acids Res.*, 2023, **51**, 8691–8710.
- 8 P. Thumbs, T. T. Ensfelder, M. Hillmeier, M. Wagner, M. Heiss, C. Scheel, A. Schön, M. Müller, S. Michalakis, S. Kellner and T. Carell, *Angew. Chem., Int. Ed.*, 2020, **59**, 12352–12356.
- 9 Š. Pospíšil, A. Panattoni, F. Gracias, V. Sýkorová, V. V. Hausnerová, D. Vítovská, H. Šanderová, L. Krásný and M. Hocek, *ACS Chem. Biol.*, 2022, **17**, 2781–2788.
- 10 J. R. Androsavich, *Nat. Rev. Drug Discovery*, 2024, **23**, 421–444.
- 11 S. Delaunay, M. Helm and M. Frye, *Nat. Rev. Genet.*, 2024, **25**, 104–122.
- 12 R. J. Ontiveros, J. Stoute and K. F. Liu, *Biochem. J.*, 2019, **476**, 1227–1245.
- 13 E. Fadda, *Curr. Opin. Chem. Biol.*, 2022, **69**, 102175.
- 14 S. S. Shivatare, V. S. Shivatare and C.-H. Wong, *Chem. Rev.*, 2022, **122**, 15603–15671.
- 15 A. Eschenmoser and M. Dobler, *Helv. Chim. Acta*, 1992, **75**, 218–259.
- 16 A. Eschenmoser, *Science*, 1999, **284**, 2118–2124.



17 C. J. Leumann, *Bioorg. Med. Chem.*, 2002, **10**, 841–854.

18 D. M. Fialho, T. P. Roche and N. V. Hud, *Chem. Rev.*, 2020, **120**, 4806–4830.

19 E. Lescrinier, M. Froeyen and P. Herdewijn, *Nucleic Acids Res.*, 2003, **31**, 2975–2989.

20 J. C. Chaput, P. Herdewijn and M. Hollenstein, *ChemBioChem*, 2020, **21**, 1408–1411.

21 T. C. Roberts, R. Langer and M. J. A. Wood, *Nat. Rev. Drug Discovery*, 2020, **19**, 673–694.

22 S. T. Crooke, X.-H. Liang, B. F. Baker and R. M. Crooke, *J. Biol. Chem.*, 2021, **296**, 100416.

23 M. C. Lauffer, W. van Roon-Mom and A. Aartsma-Rus, *Commun. Med.*, 2024, **4**, 6.

24 B. R. Leavitt and S. J. Tabrizi, *Science*, 2020, **367**, 1428–1429.

25 S. T. Crooke, B. F. Baker, R. M. Crooke and X.-H. Liang, *Nat. Rev. Drug Discovery*, 2021, **20**, 427–453.

26 E. Çakan, O. D. Lara, A. Szymanowska, E. Bayraktar, A. Chavez-Reyes, G. Lopez-Berestein, P. Amero and C. Rodriguez-Aguayo, *Cancers*, 2024, **16**, 2940.

27 A. Vaillant, *Viruses*, 2022, **14**, 2052.

28 M. Herkt and T. Thum, *Mol. Ther.*, 2021, **29**, 521–539.

29 R. S. Geary, D. Norris, R. Yu and C. F. Bennett, *Adv. Drug Delivery Rev.*, 2015, **87**, 46–51.

30 C. F. Bennett, *Annu. Rev. Med.*, 2019, **70**, 307–321.

31 D. C. Guenther, S. Mori, S. Matsuda, J. A. Gilbert, J. L. S. Willoughby, S. Hyde, A. Bisbe, Y. Jiang, S. Agarwal, M. Madaoui, M. M. Janas, K. Charisse, M. A. Maier, M. Egli and M. Manoharan, *J. Am. Chem. Soc.*, 2022, **144**, 14517–14534.

32 A. Akinc, M. A. Maier, M. Manoharan, K. Fitzgerald, M. Jayaraman, S. Barros, S. Ansell, X. Du, M. J. Hope, T. D. Madden, B. L. Mui, S. C. Semple, Y. K. Tam, M. Ciufolini, D. Witzigmann, J. A. Kulkarni, R. van der Meel and P. R. Cullis, *Nat. Nanotechnol.*, 2019, **14**, 1084–1087.

33 P. Mangla, Q. Vicentini and A. Biscans, *Cells*, 2023, **12**, 2253.

34 M. Bege and A. Borbás, *Pharmaceuticals*, 2022, **15**, 909.

35 A. J. Debacker, J. Voutila, M. Catley, D. Blakey and N. Habib, *Mol. Ther.*, 2020, **28**, 1759–1771.

36 J. K. Nair, J. L. S. Willoughby, A. Chan, K. Charisse, M. R. Alam, Q. Wang, M. Hoekstra, P. Kandasamy, A. V. Kel'in, S. Milstein, N. Taneja, J. O'Shea, S. Shaikh, L. Zhang, R. J. van der Sluis, M. E. Jung, A. Akinc, R. Hutabarat, S. Kuchimanchi, K. Fitzgerald, T. Zimmermann, T. J. C. van Berkel, M. A. Maier, K. G. Rajeev and M. Manoharan, *J. Am. Chem. Soc.*, 2014, **136**, 16958–16961.

37 L. K. McKenzie, R. El-Khoury, J. D. Thorpe, M. J. Damha and M. Hollenstein, *Chem. Soc. Rev.*, 2021, **50**, 5126–5164.

38 C. Fàbrega, A. Aviñó and R. Eritja, *Chem. Rec.*, 2022, **22**, e202100270.

39 M. Egli and M. Manoharan, *Nucleic Acids Res.*, 2023, **51**, 2529–2573.

40 J. C. Chaput and P. Herdewijn, *Angew. Chem., Int. Ed.*, 2019, **58**, 11570–11572.

41 P. Herdewijn and P. Marlière, *Chem. Biodiversity*, 2009, **6**, 791–808.

42 N. Freund, M. J. L. J. Fürst and P. Holliger, *Curr. Opin. Biotechnol.*, 2022, **74**, 129–136.

43 A. Kowalezyk, M. Piotrowicz, M. Gapińska, D. Trzybiński, K. Woźniak, T. M. Golding, T. Stringer, G. S. Smith, R. Czerwieniec and K. Kowalski, *Bioorg. Chem.*, 2022, **125**, 105847.

44 G. S. Ivanov, V. G. Tribulovich, N. B. Pestov, T. I. David, A.-S. Amoah, T. V. Korneenko and N. A. Barlev, *Biol. Direct*, 2022, **17**, 39.

45 R. A. Flynn, K. Pedram, S. A. Malaker, P. J. Batista, B. A. H. Smith, A. G. Johnson, B. M. George, K. Majzoub, P. W. Villalta, J. E. Carette and C. R. Bertozzi, *Cell*, 2021, **184**, 3109–3124.

46 K. T. Schjoldager, Y. Narimatsu, H. J. Joshi and H. Clausen, *Nat. Rev. Mol. Cell Biol.*, 2020, **21**, 729–749.

47 C. D. Hunter, T. Guo, G. Daskhan, M. R. Richards and C. W. Cairo, *Chem. Rev.*, 2018, **118**, 8188–8241.

48 M. Hocek, *Acc. Chem. Res.*, 2019, **52**, 1730–1737.

49 V. Roy and L. A. Agrofoglio, *Drug Discovery Today*, 2022, **27**, 1945–1953.

50 M. Chowdhury and R. H. E. Hudson, *Chem. Rec.*, 2023, **23**, e202200218.

51 Y. Wang and S. K. Silverman, *Angew. Chem., Int. Ed.*, 2005, **44**, 5863–5866.

52 G. Das, S. Harikrishna and K. R. Gore, *Chem. Rec.*, 2022, **22**, e202200174.

53 C. J. Leumann, *Chimia*, 2005, **59**, 776–779.

54 J. A. Kulkarni, D. Witzigmann, S. B. Thomson, S. Chen, B. R. Leavitt, P. R. Cullis and R. van der Meel, *Nat. Nanotechnol.*, 2021, **16**, 630–643.

55 R. Obexer, M. Nassir, E. R. Moody, P. S. Baran and S. L. Lovelock, *Science*, 2024, **384**, eadl4015.

56 S. K. Jana, S. Harikrishna, S. Sudhakar, R. El-Khoury, P. I. Pradeepkumar and M. J. Damha, *J. Org. Chem.*, 2022, **87**, 2367–2379.

57 A. Khvorova and J. K. Watts, *Nat. Biotechnol.*, 2017, **35**, 238–248.

58 H. Abou Assi, A. K. Rangadurai, H. Shi, B. Liu, M. C. Clay, K. Erharter, C. Kreutz, C. L. Holley and H. M. Al-Hashimi, *Nucleic Acids Res.*, 2020, **48**, 12365–12379.

59 W. Yuan, X. Shi and L. T. O. Lee, *Mol. Ther.–Nucleic Acids*, 2024, **35**, 102195.

60 K. Yadav, K. K. Sahu, S. P. E. Gnanakani, P. Sure, R. Vijayalakshmi, V. D. Sundar, V. Sharma, R. Antil, M. Jha, S. Minz, A. Bagchi and M. Pradhan, *Int. J. Biol. Macromol.*, 2023, **241**, 124582.

61 N. Ueda, T. Kawabata and K. Takemoto, *J. Heterocycl. Chem.*, 1971, **8**, 827–829.

62 M. Egli, M. Schlegel and M. Manoharan, *RNA*, 2023, **29**, 402–414.

63 P. Nielsen, L. H. Dreiøe and J. Wengel, *Bioorg. Med. Chem.*, 1995, **3**, 19–28.

64 L. Zhang and E. Meggers, *J. Am. Chem. Soc.*, 2005, **127**, 74–75.

65 L. Zhang, A. Peritz and E. Meggers, *J. Am. Chem. Soc.*, 2005, **127**, 4174–4175.

66 K. Kowalski, *Bioorg. Chem.*, 2023, **141**, 106921.



67 V. B. Pinheiro, A. I. Taylor, C. Cozens, M. Abramov, M. Renders, S. Zhang, J. C. Chaput, J. Wengel, S.-Y. Peak-Chew, S. H. McLaughlin, P. Herdewijn and P. Holliger, *Science*, 2012, **336**, 341–344.

68 C.-H. Tsai, J. Chen and J. W. Szostak, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 14598–14603.

69 J. J. Chen, C.-H. Tsai, X. Cai, A. T. Horhota, L. W. McLaughlin and J. W. Szostak, *PLoS One*, 2009, **4**, e4949.

70 M. Luo, E. Groaz, M. Froeyen, V. Pezo, F. Jaziri, P. Leonczak, G. Schepers, J. Rozenski, P. Marlière and P. Herdewijn, *J. Am. Chem. Soc.*, 2019, **141**, 10844–10851.

71 H. Asanuma, T. Toda, K. Murayama, X. Liang and H. Kashida, *J. Am. Chem. Soc.*, 2010, **132**, 14702–14703.

72 K. Murayama, H. Kashida and H. Asanuma, *Chem. Commun.*, 2015, **51**, 6500–6503.

73 H. Kashida, K. Murayama, T. Toda and H. Asanuma, *Angew. Chem., Int. Ed.*, 2011, **50**, 1285–1288.

74 F. Sato, Y. Kamiya and H. Asanuma, *J. Org. Chem.*, 2023, **88**, 796–804.

75 E. Vengut-Climent, I. Gómez-Pinto, R. Lucas, P. Peñalver, A. Aviñó, C. Fonseca Guerra, F. M. Bickelhaupt, R. Eritja, C. González and J. C. Morales, *Angew. Chem., Int. Ed.*, 2016, **55**, 8643–8647.

76 E. Vengut-Climent, P. Peñalver, R. Lucas, I. Gómez-Pinto, A. Aviñó, A. M. Muro-Pastor, E. Galbis, M. V. de Paz, C. Fonseca Guerra, F. M. Bickelhaupt, R. Eritja, C. González and J. C. Morales, *Chem. Sci.*, 2018, **9**, 3544–3554.

77 A. de Meijere, *Angew. Chem., Int. Ed. Engl.*, 1979, **18**, 809–826.

78 K. L. Seley-Radtke and M. K. Yates, *Antiviral Res.*, 2018, **154**, 66–86.

79 C. Hyun Oh and J. H. Hong, *Int. J. Pharm. Chem.*, 2006, **339**, 507–512.

80 T. Izawa, S. Nishiyama, S. Yamamura, K. Kato and T. Takita, *J. Chem. Soc., Perkin Trans. 1*, 1992, 2519–2525.

81 Y.-L. Qiu, A. Hempel, N. Camerman, A. Camerman, F. Geiser, R. G. Ptak, J. M. Breitenbach, T. Kira, L. Li, E. Gullen, Y.-C. Cheng, J. C. Drach and J. Zemlicka, *J. Med. Chem.*, 1998, **41**, 5257–5264.

82 R. J. Rybak, C. B. Hartline, Y.-L. Qiu, J. Zemlicka, E. Harden, G. Marshall, J.-P. Sommadossi and E. R. Kern, *Antimicrob. Agents Chemother.*, 2000, **44**, 1506–1511.

83 R. Wang, S. Harada, H. Mitsuya and J. Zemlicka, *J. Med. Chem.*, 2003, **46**, 4799–4802.

84 N. Ono, S. Iwayama, K. Suzuki, T. Sekiyama, H. Nakazawa, T. Tsuji, M. Okunishi, T. Daikoku and Y. Nishiyama, *Antimicrob. Agents Chemother.*, 1998, **42**, 2095–2102.

85 R. Csuk and Y. von Scholz, *Tetrahedron*, 1994, **50**, 10431–10442.

86 Y.-C. Yan, H. Zhang, K. Hu, S.-M. Zhou, Q. Chen, R.-Y. Qu and G.-F. Yang, *Bioorg. Med. Chem.*, 2022, **72**, 116968.

87 H. Zhang, P.-F. Liu, Q. Chen, Q.-Y. Wu, A. Seville, Y.-C. Gu, J. Clough, S.-L. Zhou and G.-F. Yang, *Org. Biomol. Chem.*, 2016, **14**, 3482–3485.

88 A. Zhong, Y.-H. Lee, Y.-N. Liu and H.-W. Liu, *Biochemistry*, 2021, **60**, 537–546.

89 J. Bridwell-Rabb, A. Zhong, H. G. Sun, C. L. Drennan and H.-W. Liu, *Nature*, 2017, **544**, 322–326.

90 J. An, L. P. Riel and A. R. Howell, *Acc. Chem. Res.*, 2021, **54**, 3850–3862.

91 A. Kakefuda, A. Masuda, Y. Ueno, A. Ono and A. Matsuda, *Tetrahedron*, 1996, **52**, 2863–2876.

92 N. Katagiri, Y. Morishita, I. Oosawa and M. Yamaguchi, *Tetrahedron Lett.*, 1999, **40**, 6835–6840.

93 S. Honzawa, S. Ohwada, Y. Morishita, K. Sato, N. Katagiri and M. Yamaguchi, *Tetrahedron*, 2000, **56**, 2615–2627.

94 A. M. Kawasaki, M. D. Casper, S. M. Freier, E. A. Lesnik, M. C. Zounes, L. L. Cummins, C. Gonzalez and P. D. Cook, *J. Med. Chem.*, 1993, **36**, 831–841.

95 G. F. Deleavey and M. J. Damha, *Chem. Biol.*, 2012, **19**, 937–954.

96 M. Manoharan, A. Akinc, R. K. Pandey, J. Qin, P. Hadwiger, M. John, K. Mills, K. Charisse, M. A. Maier, L. Nechev, E. M. Greene, P. S. Pallan, E. Rozners, K. G. Rajeev and M. Egli, *Angew. Chem., Int. Ed.*, 2011, **50**, 2284–2288.

97 R. V. Fucini, H. J. Haringsma, P. Deng, W. M. Flanagan and A. T. Willingham, *Nucleic Acid Ther.*, 2012, **22**, 205–210.

98 J. M. Layzer, A. P. McCaffrey, A. K. Tanner, Z. Huang, M. A. Kay and B. A. Sullenger, *RNA*, 2004, **10**, 766–771.

99 M. Manoharan, *Curr. Opin. Chem. Biol.*, 2004, **8**, 570–579.

100 J. L. Hyde and M. S. Diamond, *Virology*, 2015, **479–480**, 66–74.

101 L. L. Cummins, S. R. Owens, L. M. Risen, E. A. Lesnik, S. M. Freier, D. McGee, C. J. Guinossos and P. D. Cook, *Nucleic Acids Res.*, 1995, **23**, 2019–2024.

102 I. Yildirim, E. Kierzek, R. Kierzek and G. C. Schatz, *J. Phys. Chem. B*, 2014, **118**, 14177–14187.

103 E. T. Kool, *Chem. Rev.*, 1997, **97**, 1473–1488.

104 P. Lubini, W. Zürcher and M. Egli, *Chem. Biol.*, 1994, **1**, 39–45.

105 E. A. Lesnik, C. J. Guinossos, A. M. Kawasaki, H. Sasmor, M. Zounes, L. L. Cummins, D. J. Ecker, P. D. Cook and S. M. Freier, *Biochemistry*, 1993, **32**, 7832–7838.

106 M. Egli, G. Minasov, V. Tereshko, P. S. Pallan, M. Teplova, G. B. Inamati, E. A. Lesnik, S. R. Owens, B. S. Ross, T. P. Prakash and M. Manoharan, *Biochemistry*, 2005, **44**, 9045–9057.

107 E. Pfund, C. Dupouy, S. Rouanet, R. Legay, C. Lebargy, J.-J. Vasseur and T. Lequeux, *Org. Lett.*, 2019, **21**, 4803–4807.

108 K.-H. Altmann, D. Fabbro, N. M. Dean, T. Geiger, B. P. Monia, M. Müllert and P. Nicklin, *Biochem. Soc. Trans.*, 1996, **24**, 630–637.

109 T. P. Prakash, A. M. Kawasaki, E. V. Wancewicz, L. Shen, B. P. Monia, B. S. Ross, B. Bhat and M. Manoharan, *J. Med. Chem.*, 2008, **51**, 2766–2776.

110 R. H. Griffey, B. P. Monia, L. L. Cummins, S. Freier, M. J. Greig, C. J. Guinossos, E. Lesnik, S. M. Manalili, V. Mohan, S. Owens, B. R. Ross, H. Sasmor, E. Wancewicz, K. Weiler, P. D. Wheeler and P. D. Cook, *J. Med. Chem.*, 1996, **39**, 5100–5109.

111 M. Manoharan, T. P. Prakash, I. Barber-Peoc'h, B. Bhat, G. Vasquez, B. S. Ross and P. D. Cook, *J. Org. Chem.*, 1999, **64**, 6468–6472.

112 P. Martin, *Helv. Chim. Acta*, 1995, **78**, 486–504.



113 M. Prhavc, E. A. Lesnik, V. Mohan and M. Manoharan, *Tetrahedron Lett.*, 2001, **42**, 8777–8780.

114 R. Pattanayek, L. Sethaphong, C. Pan, M. Prhavc, T. P. Prakash, M. Manoharan and M. Egli, *J. Am. Chem. Soc.*, 2004, **126**, 15006–15007.

115 J. Winkler, M. Gilbert, A. Kocourková, M. Stessl and C. R. Noe, *ChemMedChem*, 2008, **3**, 102–110.

116 T. P. Prakash, M. Manoharan, A. M. Kawasaki, A. S. Fraser, E. A. Lesnik, N. Sioufi, J. M. Leeds, M. Teplova and M. Egli, *Biochemistry*, 2002, **41**, 11642–11648.

117 V. Tereshko, S. Portmann, E. C. Tay, P. Martin, F. Natt, K.-H. Altmann and M. Egli, *Biochemistry*, 1998, **37**, 10626–10634.

118 M. Teplova, G. Minasov, V. Tereshko, G. B. Inamati, P. D. Cook, M. Manoharan and M. Egli, *Nat. Struct. Mol. Biol.*, 1999, **6**, 535–539.

119 M. Pichon, F. Levi-Acobas, C. Kitoun and M. Hollenstein, *Chem. – Eur. J.*, 2024, **30**, e202400137.

120 R. Tomecki, K. Drazkowska, R. Madaj, A. Mamot, S. Dunin-Horkawicz and P. J. Sikorski, *ChemBioChem*, 2024, **25**, e202400202.

121 H. Aurup, D. M. Williams and F. Eckstein, *Biochemistry*, 1992, **31**, 9636–9641.

122 J. B. J. Pavey, A. J. Lawrence, I. A. O’Neil, S. Vortler and R. Cosstick, *Org. Biomol. Chem.*, 2004, **2**, 869–875.

123 Y. Masaki, H. Ito, Y. Oda, K. Yamazaki, N. Tago, K. Ohno, N. Ishii, H. Tsunoda, T. Kanamori, A. Ohkubo, M. Sekine and K. Seio, *Chem. Commun.*, 2016, **52**, 12889–12892.

124 V. Siegmund, T. Santner, R. Micura and A. Marx, *Chem. Commun.*, 2012, **48**, 9870–9872.

125 J. Chelliserrykattil and A. D. Ellington, *Nat. Biotechnol.*, 2004, **22**, 1155–1160.

126 N. Freund, A. I. Taylor, S. Arangundy-Franklin, N. Subramanian, S.-Y. Peak-Chew, A. M. Whitaker, B. D. Freudenthal, M. Abramov, P. Herdewijn and P. Holliger, *Nat. Chem.*, 2023, **15**, 91–100.

127 T. Chen, N. Hongdilokkul, Z. Liu, R. Adhikary, S. S. Tsuen and F. E. Romesberg, *Nat. Chem.*, 2016, **8**, 556–562.

128 D. Kestemont, M. Renders, P. Leonczak, M. Abramov, G. Schepers, V. B. Pinheiro, J. Rozenksi and P. Herdewijn, *Chem. Commun.*, 2018, **54**, 6408–6411.

129 N. Sabat, A. Stämpfli, S. Hanlon, S. Bisagni, F. Sladojevich, K. Püntener and M. Hollenstein, *Nat. Commun.*, 2024, **15**, 8009.

130 A. Hoose, R. Vellacott, M. Storch, P. S. Freemont and M. G. Ryadnov, *Nat. Rev. Chem.*, 2023, **7**, 144–161.

131 R. Liboska, J. Snášel, I. Barvík, M. Buděšínský, R. Pohl, Z. Točík, O. Páv, D. Rejman, P. Novák and I. Rosenberg, *Org. Biomol. Chem.*, 2011, **9**, 8261–8267.

132 E. Malek-Adamian, D. C. Guenther, S. Matsuda, S. Martínez-Montero, I. Zlatev, J. Harp, M. Burai Patrascu, D. J. Foster, J. Fakhoury, L. Perkins, N. Moitessier, R. M. Manoharan, N. Taneja, A. Bisbe, K. Charisse, M. Maier, K. G. Rajeev, M. Egli, M. Manoharan and M. J. Damha, *J. Am. Chem. Soc.*, 2017, **139**, 14542–14555.

133 J. M. Harp, D. C. Guenther, A. Bisbe, L. Perkins, S. Matsuda, G. R. Bommineni, I. Zlatev, D. J. Foster, N. Taneja, K. Charisse, M. A. Maier, K. G. Rajeev, M. Manoharan and M. Egli, *Nucleic Acids Res.*, 2018, **46**, 8090–8104.

134 K. R. Gore, G. N. Nawale, S. Harikrishna, V. G. Chittoor, S. K. Pandey, C. Höbartner, S. Patankar and P. I. Pradeepkumar, *J. Org. Chem.*, 2012, **77**, 3233–3245.

135 K. Koizumi, Y. Maeda, T. Kano, H. Yoshida, T. Sakamoto, K. Yamagishi and Y. Ueno, *Bioorg. Med. Chem.*, 2018, **26**, 3521–3534.

136 T. Kano, Y. Katsuragi, Y. Maeda and Y. Ueno, *Bioorg. Med. Chem.*, 2018, **26**, 4574–4582.

137 A. Uematsu, R. Kajino, Y. Maeda and Y. Ueno, *Nucleosides, Nucleotides Nucleic Acids*, 2020, **39**, 280–291.

138 G. N. Nawale, S. Bahadorikhali, P. Sengupta, S. Kadekar, S. Chatterjee and O. P. Varghese, *Chem. Commun.*, 2019, **55**, 9112–9115.

139 R. Kajino, Y. Maeda, H. Yoshida, K. Yamagishi and Y. Ueno, *J. Org. Chem.*, 2019, **84**, 3388–3404.

140 S. Martínez-Montero, G. F. Deleavey, A. Kulkarni, N. Martín-Pintado, P. Lindovska, M. Thomson, C. González, M. Götte and M. J. Damha, *J. Org. Chem.*, 2014, **79**, 5627–5635.

141 N. Inoue, D. Kaga, N. Minakawa and A. Matsuda, *J. Org. Chem.*, 2005, **70**, 8597–8600.

142 T. Naka, N. Minakawa, H. Abe, D. Kaga and A. Matsuda, *J. Am. Chem. Soc.*, 2000, **122**, 7233–7243.

143 N. Inoue, N. Minakawa and A. Matsuda, *Nucleic Acids Res.*, 2006, **34**, 3476–3483.

144 S. Hoshika, N. Minakawa and A. Matsuda, *Nucleic Acids Res.*, 2004, **32**, 3815–3825.

145 M. Takahashi, N. Minakawa and A. Matsuda, *Nucleic Acids Res.*, 2009, **37**, 1353–1362.

146 N. S. Tarashima, A. Matsuo and N. Minakawa, *J. Am. Chem. Soc.*, 2020, **142**, 17255–17259.

147 T. Kojima, K. Furukawa, H. Maruyama, N. Inoue, N. Tarashima, A. Matsuda and N. Minakawa, *ACS Synth. Biol.*, 2013, **2**, 529–536.

148 N. Minakawa, M. Sanji, Y. Kato and A. Matsuda, *Bioorg. Med. Chem.*, 2008, **16**, 9450–9456.

149 Y. Kato, N. Minakawa, Y. Komatsu, H. Kamiya, N. Ogawa, H. Harashima and A. Matsuda, *Nucleic Acids Res.*, 2005, **33**, 2942–2951.

150 N. Tarashima, T. Sumitomo, H. Ando, K. Furukawa, T. Ishida and N. Minakawa, *Org. Biomol. Chem.*, 2015, **13**, 6949–6952.

151 S. Smirnov, F. Johnson, R. Marumoto and C. de los Santos, *J. Biomol. Struct. Dyn.*, 2000, **17**, 981–991.

152 M. Perbost, M. Lucas, C. Chavis, A. Pompon, H. Baumgartner, B. Rayner, H. Griengl and J. L. Imbach, *Biochem. Biophys. Res. Commun.*, 1989, **165**, 742–747.

153 J. Sági, A. Szemzö, J. Szécsi and L. Ötvös, *Nucleic Acids Res.*, 1990, **18**, 2133–2140.

154 Y. Xu, K. Kino and H. Sugiyama, *J. Biomol. Struct. Dyn.*, 2002, **20**, 437–446.

155 K.-H. Altmann, M.-O. Bévierre, A. De Mesmaeker and H. E. Moser, *Bioorg. Med. Chem. Lett.*, 1995, **5**, 431–436.

156 R. W. Miles, P. C. Tyler, G. B. Evans, R. H. Furneaux, D. W. Parkin and V. L. Schramm, *Biochemistry*, 1999, **38**, 13147–13154.



157 G. B. Evans, P. C. Tyler and V. L. Schramm, *ACS Infect. Dis.*, 2018, **4**, 107–117.

158 G. B. Evans, R. H. Furneaux, G. J. Gainsford, J. C. Hanson, G. A. Kicska, A. A. Sauve, V. L. Schramm and P. C. Tyler, *J. Med. Chem.*, 2003, **46**, 155–160.

159 J. M. Mason, H. Yuan, G. B. Evans, P. C. Tyler, Q. Du and V. L. Schramm, *Eur. J. Med. Chem.*, 2017, **127**, 793–809.

160 S. Buchini and C. J. Leumann, *Curr. Opin. Chem. Biol.*, 2003, **7**, 717–726.

161 A. Häberli and C. J. Leumann, *Org. Lett.*, 2002, **4**, 3275–3278.

162 A. Häberli and C. J. Leumann, *Org. Lett.*, 2001, **3**, 489–492.

163 D. M. Tidd and H. M. Warenius, *Br. J. Cancer*, 1989, **60**, 343–350.

164 R. J. Boado and W. M. Pardridge, *Bioconjugate Chem.*, 1992, **3**, 519–523.

165 A. K. Saha, C. Waychunas, T. J. Caulfield, D. A. Upson, C. Hobbs and A. M. Yawman, *J. Org. Chem.*, 1995, **60**, 788–789.

166 G. Wang and P. J. Middleton, *Tetrahedron Lett.*, 1996, **37**, 2739–2742.

167 P. P. Seth, C. R. Allerson, A. Siwkowski, G. Vasquez, A. Berdeja, M. T. Migawa, H. Gaus, T. P. Prakash, B. Bhat and E. E. Swayze, *J. Med. Chem.*, 2010, **53**, 8309–8318.

168 T. P. Prakash, W. F. Lima, H. M. Murray, W. Li, G. A. Kinberger, A. E. Chappell, H. Gaus, P. P. Seth, B. Bhat, S. T. Crooke and E. E. Swayze, *Nucleic Acids Res.*, 2015, **43**, 2993–3011.

169 G. Clavé, M. Reverte, J.-J. Vasseur and M. Smietana, *RSC Chem. Biol.*, 2021, **2**, 94–150.

170 D. Hutter, M. O. Blaettler and S. A. Benner, *Helv. Chim. Acta*, 2002, **85**, 2777–2806.

171 T. Kofoed, P. B. Rasmussen, P. Valentin Hansen and E. B. Pedersen, *Acta Chem. Scand.*, 1997, **51**, 318–324.

172 S. Epple, A. Modi, Y. R. Baker, E. Węgrzyn, D. Traoré, P. Wanat, A. E. S. Tyburn, A. Shivalingam, L. Taemaitree, A. H. El-Sagheer and T. Brown, *J. Am. Chem. Soc.*, 2021, **143**, 16293–16301.

173 N. Z. Fantoni, A. H. El-Sagheer and T. Brown, *Chem. Rev.*, 2021, **121**, 7122–7154.

174 B. Zengin Kurt, D. Dhara, A. H. El-Sagheer and T. Brown, *Org. Lett.*, 2024, **26**, 4137–4141.

175 E. M. Huie, M. R. Kirshenbaum and G. L. Trainor, *J. Org. Chem.*, 1992, **57**, 4569–4570.

176 K. J. Fettes, N. Howard, D. T. Hickman, S. Adah, M. R. Player, P. F. Torrence and J. Micklefield, *J. Chem. Soc., Perkin Trans. 1*, 2002, 485–495, DOI: [10.1039/B110603C](https://doi.org/10.1039/B110603C).

177 E. Rozners, D. Katkevica, E. Bizdena and R. Strömberg, *J. Am. Chem. Soc.*, 2003, **125**, 12125–12136.

178 C. Pal, M. Richter and E. Rozners, *ACS Chem. Biol.*, 2024, **19**, 249–253.

179 R. L. Momparler, *Biochem. Biophys. Res. Commun.*, 1969, **34**, 465–471.

180 O. Rechkoblit, R. E. Johnson, A. Buku, L. Prakash, S. Prakash and A. K. Aggarwal, *Sci. Rep.*, 2019, **9**, 16400.

181 A. M. Noronha, C. J. Wilds, C.-N. Lok, K. Viazovkina, D. Arion, M. A. Parniak and M. J. Damha, *Biochemistry*, 2000, **39**, 7050–7062.

182 P. A. Giannaris and M. J. Damha, *Can. J. Chem.*, 1994, **72**, 909–918.

183 M. J. Damha, C. J. Wilds, A. Noronha, I. Brukner, G. Borkow, D. Arion and M. A. Parniak, *J. Am. Chem. Soc.*, 1998, **120**, 12976–12977.

184 A. Noronha and M. J. Damha, *Nucleic Acids Res.*, 1998, **26**, 2665–2671.

185 E. Medina, E. J. Yik, P. Herdewijn and J. C. Chaput, *ACS Synth. Biol.*, 2021, **10**, 1429–1437.

186 A. I. Taylor, V. B. Pinheiro, M. J. Smola, A. S. Morgunov, S. Peak-Chew, C. Cozens, K. M. Weeks, P. Herdewijn and P. Holliger, *Nature*, 2015, **518**, 427–430.

187 K. B. Wu, C. J. A. Skrodzki, Q. Su, J. Lin and J. Niu, *Chem. Sci.*, 2022, **13**, 6873–6881.

188 L. Sun, X. Ma, B. Zhang, Y. Qin, J. Ma, Y. Du and T. Chen, *RSC Chem. Biol.*, 2022, **3**, 1173–1197.

189 P. Kois, Z. Tocik, M. Spassova, W.-Y. Ren, I. Rosenberg, J. F. Soler and K. A. Watanabe, *Nucleosides, Nucleotides Nucleic Acids*, 1993, **12**, 1093–1109.

190 I. Rosenberg, J. F. Soler, Z. Tocik, W.-Y. Ren, L. A. Ciszewski, P. Kois, K. W. Pankiewicz, M. Spassova and K. A. Watanabe, *Nucleosides, Nucleotides Nucleic Acids*, 1993, **12**, 381–401.

191 R. El-Khoury and M. J. Damha, *Acc. Chem. Res.*, 2021, **54**, 2287–2297.

192 C. J. Wilds and M. J. Damha, *Nucleic Acids Res.*, 2000, **28**, 3625–3635.

193 F. Li, S. Sarkhel, C. J. Wilds, Z. Wawrzak, T. P. Prakash, M. Manoharan and M. Egli, *Biochemistry*, 2006, **45**, 4141–4152.

194 J.-F. Trempe, C. J. Wilds, A. Y. Denisov, R. T. Pon, M. J. Damha and K. Gehring, *J. Am. Chem. Soc.*, 2001, **123**, 4896–4903.

195 S. A. Ingale, P. Leonard, Q. N. Tran and F. Seela, *J. Org. Chem.*, 2015, **80**, 3124–3138.

196 C.-N. Lok, E. Viazovkina, K.-L. Min, E. Nagy, C. J. Wilds, M. J. Damha and M. A. Parniak, *Biochemistry*, 2002, **41**, 3457–3467.

197 M. E. Østergaard, J. Nichols, T. A. Dwight, W. Lima, M. E. Jung, E. E. Swayze and P. P. Seth, *Mol. Ther.-Nucleic Acids*, 2017, **7**, 20–30.

198 T. Dowler, D. Bergeron, A.-L. Tedeschi, L. Paquet, N. Ferrari and M. J. Damha, *Nucleic Acids Res.*, 2006, **34**, 1669–1675.

199 G. F. Deleavey, J. K. Watts, T. Alain, F. Robert, A. Kalota, V. Aishwarya, J. Pelletier, A. M. Gewirtz, N. Sonenberg and M. J. Damha, *Nucleic Acids Res.*, 2010, **38**, 4547–4557.

200 D. O'Reilly, Z. J. Kartje, E. A. Ageely, E. Malek-Adamian, M. Habibian, A. Schofield, C. L. Barkau, K. J. Rohilla, L. B. DeRossett, A. T. Weigle, M. J. Damha and K. T. Gagnon, *Nucleic Acids Res.*, 2018, **47**, 546–558.

201 M. J. Donde, A. M. Rochussen, S. Kapoor and A. I. Taylor, *Commun. Biol.*, 2022, **5**, 1010.

202 A. I. Taylor, C. J. K. Wan, M. J. Donde, S.-Y. Peak-Chew and P. Holliger, *Nat. Chem.*, 2022, **14**, 1295–1305.

203 C. G. Peng and M. J. Damha, *J. Am. Chem. Soc.*, 2007, **129**, 5310–5311.

204 C. G. Peng and M. J. Damha, *Can. J. Chem.*, 2008, **86**, 881–891.



205 F. Levi-Acobas, A. Katolik, P. Röthlisberger, T. Cokelaer, I. Sarac, M. J. Damha, C. J. Leumann and M. Hollenstein, *Org. Biomol. Chem.*, 2019, **17**, 8083–8087.

206 I. Alves Ferreira-Bravo, C. Cozens, P. Holliger and J. J. DeStefano, *Nucleic Acids Res.*, 2015, **43**, 9587–9599.

207 Y. Wang, A. K. Ngor, A. Nikoomanzar and J. C. Chaput, *Nat. Commun.*, 2018, **9**, 5067.

208 J. C. Chaput, *Acc. Chem. Res.*, 2021, **54**, 1056–1065.

209 K.-U. Schöning, P. Scholz, S. Guntha, X. Wu, R. Krishnamurthy and A. Eschenmoser, *Science*, 2000, **290**, 1347–1351.

210 K.-U. Schöning, P. Scholz, X. Wu, S. Guntha, G. Delgado, R. Krishnamurthy and A. Eschenmoser, *Helv. Chim. Acta*, 2002, **85**, 4111–4153.

211 P. S. Pallan, C. J. Wilds, Z. Wawrzak, R. Krishnamurthy, A. Eschenmoser and M. Egli, *Angew. Chem., Int. Ed.*, 2003, **42**, 5893–5895.

212 H. H. Lackey, E. M. Peterson, Z. Chen, J. M. Harris and J. M. Heemstra, *ACS Synth. Biol.*, 2019, **8**, 1144–1152.

213 C. J. Wilds, Z. Wawrzak, R. Krishnamurthy, A. Eschenmoser and M. Egli, *J. Am. Chem. Soc.*, 2002, **124**, 13716–13721.

214 M.-O. Ebert, C. Mang, R. Krishnamurthy, A. Eschenmoser and B. Jaun, *J. Am. Chem. Soc.*, 2008, **130**, 15105–15115.

215 J. C. Chaput and J. W. Szostak, *J. Am. Chem. Soc.*, 2003, **125**, 9274–9275.

216 L. N. Jackson, N. Chim, C. Shi and J. C. Chaput, *Nucleic Acids Res.*, 2019, **47**, 6973–6983.

217 M. R. Dunn, C. Otto, K. E. Fenton and J. C. Chaput, *ACS Chem. Biol.*, 2016, **11**, 1210–1219.

218 N. Chim, C. Shi, S. P. Sau, A. Nikoomanzar and J. C. Chaput, *Nat. Commun.*, 2017, **8**, 1810.

219 H. Yu, S. Zhang and J. C. Chaput, *Nat. Chem.*, 2012, **4**, 183–187.

220 D. Wei, Y. Wang, D. Song, Z. Zhang, J. Wang, J.-Y. Chen, Z. Li and H. Yu, *ACS Synth. Biol.*, 2022, **11**, 3874–3885.

221 Y. Wang, Y. Wang, D. Song, X. Sun, Z. Zhang, X. Li, Z. Li and H. Yu, *J. Am. Chem. Soc.*, 2021, **143**, 8154–8163.

222 Y. Wang, K. Nguyen, R. C. Spitale and J. C. Chaput, *Nat. Chem.*, 2021, **13**, 319–326.

223 M. Gao, D. Wei, S. Chen, B. Qin, Y. Wang, Z. Li and H. Yu, *ChemBioChem*, 2023, **24**, e202200651.

224 A. Lozoya-Colinas, Y. Yu and J. C. Chaput, *J. Am. Chem. Soc.*, 2023, **145**, 25789–25796.

225 M. C. Culbertson, K. W. Temburnikar, S. P. Sau, J.-Y. Liao, S. Bala and J. C. Chaput, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 2418–2421.

226 E. M. Lee, N. A. Setterholm, M. Hajjar, B. Barpuzary and J. C. Chaput, *Nucleic Acids Res.*, 2023, **51**, 9542–9551.

227 S. Matsuda, S. Bala, J.-Y. Liao, D. Datta, A. Mikami, L. Woods, J. M. Harp, J. A. Gilbert, A. Bisbe, R. M. Manoharan, M. Kim, C. S. Theile, D. C. Guenther, Y. Jiang, S. Agarwal, R. Maganti, M. K. Schlegel, I. Zlatev, K. Charisse, K. G. Rajeev, A. Castoreno, M. Maier, M. M. Janas, M. Egli, J. C. Chaput and M. Manoharan, *J. Am. Chem. Soc.*, 2023, **145**, 19691–19706.

228 F. Wang, L. S. Liu, C. H. Lau, T. J. Han Chang, D. Y. Tam, H. M. Leung, C. Tin and P. K. Lo, *ACS Appl. Mater. Interfaces*, 2019, **11**, 38510–38518.

229 F. Wang, L. S. Liu, P. Li, C. H. Lau, H. M. Leung, Y. R. Chin, C. Tin and P. K. Lo, *Mater. Today Bio*, 2022, **15**, 100299.

230 M. Maiti, M. Maiti, C. Knies, S. Dumbre, E. Lescrinier, H. Rosemeyer, A. Ceulemans and P. Herdewijn, *Nucleic Acids Res.*, 2015, **43**, 7189–7200.

231 H. Rosemeyer and F. Seela, *Helv. Chim. Acta*, 1991, **74**, 748–760.

232 F. Seela, M. Heckel and H. Rosemeyer, *Helv. Chim. Acta*, 1996, **79**, 1451–1461.

233 D. J. Sharpe, K. Röder and D. J. Wales, *J. Phys. Chem. B*, 2020, **124**, 4062–4068.

234 S. Ivanov, Y. Alekseev, J. R. Bertrand, C. Malvy and M. B. Gottikh, *Nucleic Acids Res.*, 2003, **31**, 4256–4263.

235 B. Ravindra Babu, Rounak, N. E. Poopeiko, M. Juhl, A. D. Bond, V. S. Parmar and J. Wengel, *Eur. J. Org. Chem.*, 2005, 2297–2321.

236 N. E. Poopeiko, M. Juhl, B. Vester, M. D. Sørensen and J. Wengel, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 2285–2290.

237 B. Bauwens, J. Rozenski, P. Herdewijn and J. Robben, *ChemBioChem*, 2018, **19**, 2410–2420.

238 M. Maiti, V. Siegmund, M. Abramov, E. Lescrinier, H. Rosemeyer, M. Froeyen, A. Ramaswamy, A. Ceulemans, A. Marx and P. Herdewijn, *Chem. – Eur. J.*, 2012, **18**, 869–879.

239 A. Eschenmoser, *Angew. Chem., Int. Ed.*, 2011, **50**, 12412–12472.

240 M. Stoop, G. Meher, P. Karri and R. Krishnamurthy, *Chem. – Eur. J.*, 2013, **19**, 15336–15345.

241 T. Efthymiou, J. Gavette, M. Stoop, F. De Riccardis, M. Froeyen, P. Herdewijn and R. Krishnamurthy, *Chem. – Eur. J.*, 2018, **24**, 12811–12819.

242 A. Eschenmoser and E. Loewenthal, *Chem. Soc. Rev.*, 1992, **21**, 1–16.

243 N. Nogal, M. Sanz-Sánchez, S. Vela-Gallego, K. Ruiz-Mirazo and A. de la Escosura, *Chem. Soc. Rev.*, 2023, **52**, 7359–7388.

244 M. Böhringer, H.-J. Roth, J. Hunziker, M. Göbel, R. Krishnan, A. Giger, B. Schweizer, J. Schreiber, C. Leumann and A. Eschenmoser, *Helv. Chim. Acta*, 1992, **75**, 1416–1477.

245 K. Augustyns, A. van Aerschot, C. Urbanke and P. Herdewijn, *Bull. Soc. Chim. Belg.*, 1992, **101**, 119–130.

246 J. Hunziker, H.-J. Roth, M. Böhringer, A. Giger, U. Diederichsen, M. Göbel, R. Krishnan, B. Jaun, C. Leumann and A. Eschenmoser, *Helv. Chim. Acta*, 1993, **76**, 259–352.

247 M. Egli, P. S. Pallan, R. Pattanayek, C. J. Wilds, P. Lubini, G. Minasov, M. Dobler, C. J. Leumann and A. Eschenmoser, *J. Am. Chem. Soc.*, 2006, **128**, 10847–10856.

248 M. Froeyen, E. Lescrinier, L. Kerremans, H. Rosemeyer, F. Seela, B. Verbeure, I. Lagoja, J. Rozenski, A. Van Aerschot, R. Busson and P. Herdewijn, *Chem. – Eur. J.*, 2001, **7**, 5183–5194.

249 I. Verheggen, A. Van Aerschot, S. Toppet, R. Snoeck, G. Janssen, J. Balzarini, E. De Clercq and P. Herdewijn, *J. Med. Chem.*, 1993, **36**, 2033–2040.

250 A. Aerschot Van, I. Verheggen, C. Hendrix and P. Herdewijn, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**, 1338–1339.

251 C. Paolella, D. D'Alonzo, G. Schepers, A. Van Aerschot, G. Di Fabio, G. Palumbo, P. Herdewijn and A. Guaragna, *Org. Biomol. Chem.*, 2015, **13**, 10041–10049.



252 C. Hendrix, H. Rosemeyer, B. De Bouvere, A. Van Aerschot, F. Seela and P. Herdewijn, *Chem. – Eur. J.*, 1997, **3**, 1513–1520.

253 N. Hossain, B. Wroblowski, A. Van Aerschot, J. Rozenski, A. De Bruyn and P. Herdewijn, *J. Org. Chem.*, 1998, **63**, 1574–1582.

254 E. Lescrinier, R. Esnouf, J. Schraml, R. Busson, H. A. Heus, C. W. Hilbers and P. Herdewijn, *Chem. Biol.*, 2000, **7**, 719–731.

255 L. Kerremans, G. Schepers, J. Rozenski, R. Busson, A. Van Aerschot and P. Herdewijn, *Org. Lett.*, 2001, **3**, 4129–4132.

256 H. Kang, M. H. Fisher, D. Xu, Y. J. Miyamoto, A. Marchand, A. Van Aerschot, P. Herdewijn and R. L. Juliano, *Nucleic Acids Res.*, 2004, **32**, 4411–4419.

257 E. Eremeeva, A. Fikatas, L. Margamuljana, M. Abramov, D. Schols, E. Groaz and P. Herdewijn, *Nucleic Acids Res.*, 2019, **47**, 4927–4939.

258 A. I. Taylor, F. Beuron, S.-Y. Peak-Chew, E. P. Morris, P. Herdewijn and P. Holliger, *ChemBioChem*, 2016, **17**, 1107–1110.

259 H. D. Winter, E. Lescrinier, A. V. Aerschot and P. Herdewijn, *J. Am. Chem. Soc.*, 1998, **120**, 5381–5394.

260 B. Allart, K. Khan, H. Rosemeyer, G. Schepers, C. Hendrix, K. Rothenbacher, F. Seela, A. Van Aerschot and P. Herdewijn, *Chem. – Eur. J.*, 1999, **5**, 2424–2431.

261 M. Ovaere, J. Sponer, J. E. Sponer, P. Herdewijn and L. Van Meervelt, *Nucleic Acids Res.*, 2012, **40**, 7573–7583.

262 B. T. Le, S. X. Chen, M. Abramov, P. Herdewijn and R. N. Veedu, *Chem. Commun.*, 2016, **52**, 13467–13470.

263 Y. Maurinsh, H. Rosemeyer, R. Esnouf, A. Medvedovici, J. Wang, G. Ceulemans, E. Lescrinier, C. Hendrix, R. Busson, P. Sandra, F. Seela, A. Van Aerschot and P. Herdewijn, *Chem. – Eur. J.*, 1999, **5**, 2139–2150.

264 J. Wang, B. Verbeure, I. Luyten, E. Lescrinier, M. Froeyen, C. Hendrix, H. Rosemeyer, F. Seela, A. Van Aerschot and P. Herdewijn, *J. Am. Chem. Soc.*, 2000, **122**, 8595–8602.

265 B. Verbeure, E. Lescrinier, J. Wang and P. Herdewijn, *Nucleic Acids Res.*, 2001, **29**, 4941–4947.

266 J. Wang, D. Viña, R. Busson and P. Herdewijn, *J. Org. Chem.*, 2003, **68**, 4499–4505.

267 Y. Moai and T. Kodama, *Tetrahedron Lett.*, 2020, **61**, 151708.

268 P. P. Seth, J. Yu, A. Jazayeri, P. S. Pallan, C. R. Allerson, M. E. Østergaard, F. Liu, P. Herdewijn, M. Egli and E. E. Swayne, *J. Org. Chem.*, 2012, **77**, 5074–5085.

269 Y. Kitamura, S. Moribe and Y. Kitade, *Bioorg. Med. Chem. Lett.*, 2018, **28**, 3174–3176.

270 S. Pitsch, S. Wendeborn, B. Jaun and A. Eschenmoser, *Helv. Chim. Acta*, 1993, **76**, 2161–2183.

271 S. Pitsch, R. Krishnamurthy, M. Bolli, S. Wendeborn, A. Holzner, M. Minton, C. Lesueur, I. Schlönvogt, B. Jaun and A. Eschenmoser, *Helv. Chim. Acta*, 1995, **78**, 1621–1635.

272 I. Schlönvogt, S. Pitsch, C. Lesueur, A. Eschenmoser, B. Jaun and R. M. Wolf, *Helv. Chim. Acta*, 1996, **79**, 2316–2345.

273 M. O. Ebert and B. Jaun, *Chem. Biodiversity*, 2010, **7**, 2103–2128.

274 P. S. Pallan, P. Lubini, M. Bolli and M. Egli, *Nucleic Acids Res.*, 2007, **35**, 6611–6624.

275 M. Bolli, R. Micura, S. Pitsch and A. Eschenmoser, *Helv. Chim. Acta*, 1997, **80**, 1901–1951.

276 M. Beier, F. Reck, T. Wagner, R. Krishnamurthy and A. Eschenmoser, *Science*, 1999, **283**, 699–703.

277 F. Reck, H. Wippo, R. Kudick, M. Bolli, G. Ceulemans, R. Krishnamurthy and A. Eschenmoser, *Org. Lett.*, 1999, **1**, 1531–1534.

278 E. P. Stinchak, J. E. Summerton and D. D. Weller, *Nucleic Acids Res.*, 1989, **17**, 6129–6141.

279 J. Summerton, *Biochim. Biophys. Acta, Gene Struct. Expression*, 1999, **1489**, 141–158.

280 L. Lacroix, P. B. Arimondo, M. Takasugi, C. Hélène and J.-L. Mergny, *Biochem. Biophys. Res. Commun.*, 2000, **270**, 363–369.

281 H. Torigoe, K. Sasaki and T. Katayama, *J. Biochem.*, 2009, **146**, 173–183.

282 R. M. Hudziak, E. Barofsky, D. F. Barofsky, D. L. Weller, S.-B. Huang and D. D. Weller, *Antisense Nucleic Acid Drug Dev.*, 1996, **6**, 267–272.

283 D. Stein, E. Foster, S.-B. Huang, D. D. Weller and J. Summerton, *Antisense Nucleic Acid Drug Dev.*, 1997, **7**, 151–157.

284 Y. Miao, C. Fu, Z. Yu, L. Yu, Y. Tang and M. Wei, *Acta Pharm. Sin. B*, 2024, **14**, 3802–3817.

285 A. Ghosh, A. Banerjee, S. Gupta and S. Sinha, *J. Am. Chem. Soc.*, 2024, **146**, 32989–33001.

286 K. W. Knouse, J. N. deGruyter, M. A. Schmidt, B. Zheng, J. C. Vantourout, C. Kingston, S. E. Mercer, I. M. McDonald, R. E. Olson, Y. Zhu, C. Hang, J. Zhu, C. Yuan, Q. Wang, P. Park, M. D. Eastgate and P. S. Baran, *Science*, 2018, **361**, 1234–1238.

287 J. Rihon, C. A. Mattelaer, R. W. Montalvão, M. Froeyen, V. B. Pinheiro and E. Lescrinier, *Nucleic Acids Res.*, 2024, **52**, 2836–2847.

288 H. K. Langner, K. Jastrzebska and M. H. Caruthers, *J. Am. Chem. Soc.*, 2020, **142**, 16240–16253.

289 B. T. Le, S. Paul, K. Jastrzebska, H. Langer, M. H. Caruthers and R. N. Veedu, *Proc. Natl. Acad. Sci. U. S. A.*, 2022, **119**, e2207956119.

290 M. Tarköy, M. Bolli, B. Schweizer and C. Leumann, *Helv. Chim. Acta*, 1993, **76**, 481–510.

291 M. Tarköy and C. Leumann, *Angew. Chem., Int. Ed. Engl.*, 1993, **32**, 1432–1434.

292 M. Bolli, H. U. Trafelet and C. Leumann, *Nucleic Acids Res.*, 1996, **24**, 4660–4667.

293 M. Bolli, J. Christopher Litten, R. Schütz and C. J. Leumann, *Chem. Biol.*, 1996, **3**, 197–206.

294 M. Tarköy, M. Bolli and C. Leumann, *Helv. Chim. Acta*, 1994, **77**, 716–744.

295 P. S. Pallan, D. Ittig, A. Héroux, Z. Wawrzak, C. J. Leumann and M. Egli, *Chem. Commun.*, 2008, 883–885, DOI: [10.1039/B716390H](https://doi.org/10.1039/B716390H).

296 R. Meier, S. Grüschen and C. Leumann, *Helv. Chim. Acta*, 1999, **82**, 1813–1828.

297 B. Dugovic and C. J. Leumann, *J. Org. Chem.*, 2014, **79**, 1271–1279.

298 R. Steffens and C. Leumann, *Helv. Chim. Acta*, 1997, **80**, 2426–2439.



299 R. Steffens and C. J. Leumann, *J. Am. Chem. Soc.*, 1999, **121**, 3249–3255.

300 A. Istrate, S. Johannsen, A. Istrate, R. K. O. Sigel and C. J. Leumann, *Nucleic Acids Res.*, 2019, **47**, 4872–4882.

301 D. Renneberg and C. J. Leumann, *J. Am. Chem. Soc.*, 2002, **124**, 5993–6002.

302 A. Goyenvalle, G. Griffith, A. Babbs, S. E. Andaloussi, K. Ezzat, A. Avril, B. Dugovic, R. Chaussenot, A. Ferry, T. Voit, H. Amthor, C. Bühr, S. Schürch, M. J. A. Wood, K. E. Davies, C. Vaillend, C. Leumann and L. Garcia, *Nat. Med.*, 2015, **21**, 270–275.

303 F. Bizot, T. Tensorer, L. Garcia and A. Goyenvalle, *Nucleic Acid Ther.*, 2023, **33**, 374–380.

304 J. Lietard and C. J. Leumann, *J. Org. Chem.*, 2012, **77**, 4566–4577.

305 A. Istrate, A. Katolik, A. Istrate and C. J. Leumann, *Chem. – Eur. J.*, 2017, **23**, 10310–10318.

306 M. Hollenstein and C. J. Leumann, *ChemBioChem*, 2014, **15**, 1901–1904.

307 S. Diafa, D. Evéquoz, C. J. Leumann and M. Hollenstein, *Chem. – Asian J.*, 2017, **12**, 1347–1352.

308 M. A. Campbell and J. Wengel, *Chem. Soc. Rev.*, 2011, **40**, 5680–5689.

309 S. Obika, D. Nanbu, Y. Hari, J.-I. Andoh, K.-I. Morio, T. Doi and T. Imanishi, *Tetrahedron Lett.*, 1998, **39**, 5401–5404.

310 S. K. Singh, A. A. Koshkin, J. Wengel and P. Nielsen, *Chem. Commun.*, 1998, 455–456, DOI: [10.1039/A708608C](https://doi.org/10.1039/A708608C).

311 A. A. Koshkin, S. K. Singh, P. Nielsen, V. K. Rajwanshi, R. Kumar, M. Meldgaard, C. E. Olsen and J. Wengel, *Tetrahedron*, 1998, **54**, 3607–3630.

312 A. A. Koshkin, P. Nielsen, M. Meldgaard, V. K. Rajwanshi, S. K. Singh and J. Wengel, *J. Am. Chem. Soc.*, 1998, **120**, 13252–13253.

313 J. Duschmalé, H. F. Hansen, M. Duschmalé, E. Koller, N. Albaek, M. R. Møller, K. Jensen, T. Koch, J. Wengel and K. Bleicher, *Nucleic Acids Res.*, 2019, **48**, 63–74.

314 M. Shin, I. L. Chan, Y. Cao, A. M. Gruntman, J. Lee, J. Sousa, T. C. Rodríguez, D. Echeverria, G. Devi, A. J. Debacker, M. P. Moazami, P. M. Krishnamurthy, J. M. Rembetsky-Brown, K. Kelly, O. Yukselen, E. Donnard, T. J. Parsons, A. Khvorova, E. J. Sontheimer, R. Maehr, M. Garber and J. K. Watts, *Nucleic Acids Res.*, 2022, **50**, 8418–8430.

315 J. Elmén, H. Thonberg, K. Ljungberg, M. Frieden, M. Westergaard, Y. Xu, B. Wahren, Z. Liang, H. Ørum, T. Koch and C. Wahlestedt, *Nucleic Acids Res.*, 2005, **33**, 439–447.

316 H. Iribe, K. Miyamoto, T. Takahashi, Y. Kobayashi, J. Leo, M. Aida and K. Ui-Tei, *ACS Omega*, 2017, **2**, 2055–2064.

317 C. R. Cromwell, K. Sung, J. Park, A. R. Krysler, J. Jovel, S. K. Kim and B. P. Hubbard, *Nat. Commun.*, 2018, **9**, 1448.

318 M. Kuwahara, S. Obika, J.-I. Nagashima, Y. Ohta, Y. Suto, H. Ozaki, H. Sawai and T. Imanishi, *Nucleic Acids Res.*, 2008, **36**, 4257–4265.

319 R. N. Veedu, B. Vester and J. Wengel, *New J. Chem.*, 2010, **34**, 877–879.

320 R. N. Veedu, B. Vester and J. Wengel, *J. Am. Chem. Soc.*, 2008, **130**, 8124–8125.

321 N. Sabat, D. Katkevica, K. Pajuste, M. Flamme, A. Stämpfli, M. Katkevics, S. Hanlon, S. Bisagni, K. Püntener, F. Sladojevich and M. Hollenstein, *Front. Chem.*, 2023, **11**, 1161462.

322 M. Flamme, S. Hanlon, H. Iding, K. Puentener, F. Sladojevich and M. Hollenstein, *Bioorg. Med. Chem. Lett.*, 2021, **48**, 128242.

323 H. Hoshino, Y. Kasahara, M. Kuwahara and S. Obika, *J. Am. Chem. Soc.*, 2020, **142**, 21530–21537.

324 S. A. Burel, C. E. Hart, P. Cauntay, J. Hsiao, T. Machemer, M. Katz, A. Watt, H.-H. Bui, H. Younis, M. Sabripour, S. M. Freier, G. Hung, A. Dan, T. P. Prakash, P. P. Seth, E. E. Swayze, C. F. Bennett, S. T. Crooke and S. P. Henry, *Nucleic Acids Res.*, 2015, **44**, 2093–2109.

325 E. E. Swayze, A. M. Siwkowski, E. V. Wancewicz, M. T. Migawa, T. K. Wyrzykiewicz, G. Hung, B. P. Monia and A. C. F. Bennett, *Nucleic Acids Res.*, 2006, **35**, 687–700.

326 D. Sabatino and M. J. Damha, *J. Am. Chem. Soc.*, 2007, **129**, 8259–8270.

327 M. Habibian, S. Martínez-Montero, G. Portella, Z. Chua, D. S. Bohle, M. Orozco and M. J. Damha, *Org. Lett.*, 2015, **17**, 5416–5419.

328 Y. Y. Zheng, Y. Wu, T. J. Begley and J. Sheng, *RSC Chem. Biol.*, 2021, **2**, 990–1003.

329 C.-X. Song, K. E. Szulwach, Y. Fu, Q. Dai, C. Yi, X. Li, Y. Li, C.-H. Chen, W. Zhang, X. Jian, J. Wang, L. Zhang, T. J. Looney, B. Zhang, L. A. Godley, L. M. Hicks, B. T. Lahn, P. Jin and C. He, *Nat. Biotechnol.*, 2011, **29**, 68–72.

330 J. Josse and A. Kornberg, *J. Biol. Chem.*, 1962, **237**, 1968–1976.

331 C. Reily, T. J. Stewart, M. B. Renfrow and J. Novak, *Nat. Rev. Nephrol.*, 2019, **15**, 346–366.

332 Y.-J. Lee, N. Dai, S. E. Walsh, S. Müller, M. E. Fraser, K. M. Kauffman, C. Guan, I. R. Corrêa and P. R. Weigle, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, E3116–E3125.

333 T. Carell, C. Brandmayr, A. Hienzsch, M. Müller, D. Pearson, V. Reiter, I. Thoma, P. Thumbs and M. Wagner, *Angew. Chem., Int. Ed.*, 2012, **51**, 7110–7131.

334 E. K. Borchardt, N. M. Martinez and W. V. Gilbert, *Annu. Rev. Genet.*, 2020, **54**, 309–336.

335 H. Kasai, K. Nakanishi, R. D. Macfarlane, D. F. Torgerson, Z. Ohashi, J. A. McCloskey, H. J. Gross and S. Nishimura, *J. Am. Chem. Soc.*, 1976, **98**, 5044–5046.

336 J. C. Salazar, A. Ambrogelly, P. F. Crain, J. A. McCloskey and D. Söll, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 7536–7541.

337 M. Blaise, H. D. Becker, J. Lapointe, C. Cambillau, R. Giegé and D. Kern, *Biochimie*, 2005, **87**, 847–861.

338 A. Hienzsch, C. Deiml, V. Reiter and T. Carell, *Chem. – Eur. J.*, 2013, **19**, 4244–4248.

339 M. Hillmeier, M. Wagner, T. Ensfelder, E. Korytiakova, P. Thumbs, M. Müller and T. Carell, *Nat. Commun.*, 2021, **12**, 7123.

340 Y. Sun, M. Piechotta, I. Naarmann-de Vries, C. Dieterich and A. E. Ehrenhofer-Murray, *Nucleic Acids Res.*, 2023, **51**, 11197–11212.



341 X. Zhao, D. Ma, K. Ishiguro, H. Saito, S. Akichika, I. Matsuzawa, M. Mito, T. Irie, K. Ishibashi, K. Wakabayashi, Y. Sakaguchi, T. Yokoyama, Y. Mishima, M. Shirouzu, S. Iwasaki, T. Suzuki and T. Suzuki, *Cell*, 2023, **186**, 5517–5535.e5524.

342 T. Suzuki, A. Ogizawa, K. Ishiguro and A. Nagao, *Cell Chem. Biol.*, 2024, DOI: [10.1016/j.chembiol.2024.11.004](https://doi.org/10.1016/j.chembiol.2024.11.004).

343 A. Biela, A. Hammermeister, I. Kaczmarczyk, M. Walczak, L. Koziej, T.-Y. Lin and S. Glatt, *J. Biol. Chem.*, 2023, **299**, 104966.

344 Y. Xie, P. Chai, N. A. Till, H. Hemberger, C. G. Lebedenko, J. Porat, C. P. Watkins, R. M. Caldwell, B. M. George, J. Perr, C. R. Bertozi, B. A. Garcia and R. A. Flynn, *Cell*, 2024, **187**, 5228–5237.

345 N. Zhang, W. Tang, L. Torres, X. Wang, Y. Ajaj, L. Zhu, Y. Luan, H. Zhou, Y. Wang, D. Zhang, V. Kurbatov, S. A. Khan, P. Kumar, A. Hidalgo, D. Wu and J. Lu, *Cell*, 2024, **187**, 846–860.

346 J.-H. Xue, G.-D. Chen, F. Hao, H. Chen, Z. Fang, F.-F. Chen, B. Pang, Q.-L. Yang, X. Wei, Q.-Q. Fan, C. Xin, J. Zhao, X. Deng, B.-A. Wang, X.-J. Zhang, Y. Chu, H. Tang, H. Yin, W. Ma, L. Chen, J. Ding, E. Weinhold, R. M. Kohli, W. Liu, Z.-J. Zhu, K. Huang, H. Tang and G.-L. Xu, *Nature*, 2019, **569**, 581–585.

347 A. A. Hossain, Y. Z. Pigli, C. F. Baca, S. Heissel, A. Thomas, V. K. Libis, J. Burian, J. S. Chappie, S. F. Brady, P. A. Rice and L. A. Marraffini, *Nature*, 2024, **629**, 410–416.

348 P. Weigle and E. A. Raleigh, *Chem. Rev.*, 2016, **116**, 12655–12687.

349 G. Hutinet, Y.-J. Lee, V. D. Crécy-Lagard and P. R. Weigle, *EcoSal Plus*, 2021, **9**, eESP-0028.

350 D. Swinton, S. Hattman, R. Benzinger, V. Buchanan-Wollaston and J. Beringer, *FEBS Lett.*, 1985, **184**, 294–298.

351 J. A. Thomas, J. Orwenyo, L.-X. Wang and L. W. Black, *Viruses*, 2018, **10**, 313.

352 I. R. Lehman and E. A. Pratt, *J. Biol. Chem.*, 1960, **235**, 3254–3259.

353 C. L. Bair, D. Rifat and L. W. Black, *J. Mol. Biol.*, 2007, **366**, 779–789.

354 J. Gommers-Ampt, J. Lutgerink and P. Borst, *Nucleic Acids Res.*, 1991, **19**, 1745–1751.

355 P. Borst and R. Sabatini, *Annu. Rev. Microbiol.*, 2008, **62**, 235–251.

356 J. H. Gommers-Ampt, F. Van Leeuwen, A. L. de Beer, J. F. Vliegenthart, M. Dizdaroglu, J. A. Kowalak, P. F. Crain and P. Borst, *Cell*, 1993, **75**, 1129–1136.

357 Henri G. A. M. van Luenen, C. Farris, S. Jan, P.-A. Genest, P. Tripathi, A. Velds, Ron M. Kerkhoven, M. Nieuwland, A. Haydock, G. Ramasamy, S. Vainio, T. Heidebrecht, A. Perrakis, L. Pagie, B. van Steensel, Peter J. Myler and P. Borst, *Cell*, 2012, **150**, 909–921.

358 F. van Leeuwen, E. R. Wijsman, E. Kuyl-Yeheskiely, G. A. van der Marel, J. H. van Boom and P. Borst, *Nucleic Acids Res.*, 1996, **24**, 2476–2482.

359 R. Kieft, Y. Zhang, A. P. Marand, J. D. Moran, R. Bridger, L. Wells, R. J. Schmitz and R. Sabatini, *PLoS Genet.*, 2020, **16**, e1008390.

360 M. Ehrlich and K. C. Ehrlich, *J. Biol. Chem.*, 1981, **256**, 9966–9972.

361 A. M. Kropinski, D. Turner, J. H. E. Nash, H.-W. Ackermann, E. J. Lingohr, R. A. Warren, K. C. Ehrlich and M. Ehrlich, *Viruses*, 2018, **10**, 217.

362 A. Chakrapani, O. Ruiz-Larrabeiti, R. Pohl, M. Svoboda, L. Krásný and M. Hocek, *Chem. – Eur. J.*, 2022, **28**, e202200911.

363 M. Krömer, L. P. Slavětínská and M. Hocek, *Chem. – Eur. J.*, 2024, **30**, e202402318.

364 D. Dhara, L. A. Mular and M. Hollenstein, *Carbohydr. Res.*, 2023, **534**, 108985.

365 M. Chen, Z. Guo, J. Sun, W. Tang, M. Wang, Y. Tang, P. Li, B. Wu and Y. Chen, *Acta Pharm. Sin. B*, 2023, **13**, 765–774.

366 M. Chen, Z. Cao, W. Tang, M. Wang, Y. Chen and Z. Guo, *J. Antibiot.*, 2022, **75**, 172–175.

367 A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver and C. C. Mello, *Nature*, 1998, **391**, 806–811.

368 M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel and A. Ribas, *Nature*, 2010, **464**, 1067–1070.

369 J. M. Sasso, B. J. B. Ambrose, R. Tenchov, R. S. Datta, M. T. Basel, R. K. DeLong and Q. A. Zhou, *J. Med. Chem.*, 2022, **65**, 6975–7015.

370 V. Genna, L. Reyes-Fraile, J. Iglesias-Fernandez and M. Orozco, *Curr. Opin. Struct. Biol.*, 2024, **87**, 102838.

371 B. Hu, L. Zhong, Y. Weng, L. Peng, Y. Huang, Y. Zhao and X.-J. Liang, *Signal Transduction Targeted Ther.*, 2020, **5**, 101.

372 J. Belgrad, H. H. Fakih and A. Khvorova, *Nucleic Acid Ther.*, 2024, **34**, 52–72.

373 D. M. Copolovici, K. Langel, E. Eriste and Ü. Langel, *ACS Nano*, 2014, **8**, 1972–1994.

374 D. Kodr, E. Kužmová, R. Pohl, T. Kraus and M. Hocek, *Chem. Sci.*, 2023, **14**, 4059–4069.

375 E.-A. Kusznir, J.-C. Hau, M. Portmann, A.-G. Reinhart, F. Falivene, J. Bastien, J. Worm, A. Ross, M. Lauer, P. Ringler, F. Sladojevich, S. Huber, K. Bleicher and M. Keller, *Bioconjugate Chem.*, 2023, **34**, 866–879.

376 B. R. Meade, K. Gogoi, A. S. Hamil, C. Palm-Apergi, A. V. D. Berg, J. C. Hagopian, A. D. Springer, A. Eguchi, A. D. Kacsinta, C. F. Dowdy, A. Presente, P. Lönn, M. Kaulich, N. Yoshioka, E. Gros, X.-S. Cui and S. F. Dowdy, *Nat. Biotechnol.*, 2014, **32**, 1256–1261.

377 K. K. Ray, R. S. Wright, D. Kallend, W. Koenig, L. A. Leiter, F. J. Raal, J. A. Bisch, T. Richardson, M. Jaros, P. L. J. Wijngaard and J. J. P. Kastelein, *N. Engl. J. Med.*, 2020, **382**, 1507–1519.

378 V. Kumar and W. B. Turnbull, *Chem. Soc. Rev.*, 2023, **52**, 1273–1287.

379 V. Jadhav, A. Vaishnav, K. Fitzgerald and M. A. Maier, *Nat. Biotechnol.*, 2024, **42**, 394–405.

380 A. Novoa and N. Winssinger, *Beilstein J. Org. Chem.*, 2015, **11**, 707–719.

381 N. Spinelli, E. Defrancq and F. Morvan, *Chem. Soc. Rev.*, 2013, **42**, 4557–4573.

382 B. Ugarte-Uribe, S. Pérez-Rentero, R. Lucas, A. Aviñó, J. J. Reina, I. Alkorta, R. Eritja and J. C. Morales, *Bioconjugate Chem.*, 2010, **21**, 1280–1287.



383 A. Aviño, S. M. Ocampo, R. Lucas, J. J. Reina, J. C. Morales, J. C. Perales and R. Eritja, *Mol. Diversity*, 2011, **15**, 751–757.

384 G. Pourceau, A. Meyer, J.-J. Vasseur and F. Morvan, *J. Org. Chem.*, 2009, **74**, 1218–1222.

385 A. Kiviniemi, P. Virta, M. S. Drenichev, S. N. Mikhailov and H. Lönnberg, *Bioconjugate Chem.*, 2011, **22**, 1249–1255.

386 M. Pichon and M. Hollenstein, *Commun. Chem.*, 2024, **7**, 138.

387 M. Hollenstein, *Nat. Biotechnol.*, 2024, DOI: [10.1038/s41587-024-02322-z](https://doi.org/10.1038/s41587-024-02322-z).

388 D. J. Wiegand, J. Rittichier, E. Meyer, H. Lee, N. J. Conway, D. Ahlstedt, Z. Yurtsever, D. Rainone, E. Kuru and G. M. Church, *Nat. Biotechnol.*, 2024, DOI: [10.1038/s41587-024-02244-w](https://doi.org/10.1038/s41587-024-02244-w).

389 E. R. Moody, R. Obexer, F. Nickl, R. Spiess and S. L. Lovelock, *Science*, 2023, **380**, 1150–1154.

390 C. Nybro Dansholm, S. Meier and S. R. Beerens, *ChemBioChem*, 2024, **25**, e202300832.

391 D. Larsen and S. R. Beerens, *Chem. – Eur. J.*, 2020, **26**, 11032–11038.

392 A. Debon, E. Sirola and R. Snajdrova, *JACS Au*, 2023, **3**, 1267–1283.

393 P. Röthlisberger, F. Levi-Acobas, I. Sarac, R. Ricoux, J. P. Mahy, P. Herdewijn, P. Marlière and M. Hollenstein, *Tetrahedron Lett.*, 2018, **59**, 4241–4244.

394 S. Agrawal, *Nucleic Acid Ther.*, 2024, **34**, 37–51.

395 J. A. Reyes-Darias, F. J. Sánchez-Luque, J. C. Morales, S. Pérez-Rentero, R. Eritja and A. Berzal-Herranz, *Chem-BioChem*, 2015, **16**, 584–591.

396 E. Vengut-Climent, M. Terrazas, R. Lucas, M. Arévalo-Ruiz, R. Eritja and J. C. Morales, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 4048–4051.

397 H. Jung, G. Yu and H. Mok, *Appl. Biol. Chem.*, 2016, **59**, 759–763.

398 K. Uehara, T. Harumoto, A. Makino, Y. Koda, J. Iwano, Y. Suzuki, M. Tanigawa, H. Iwai, K. Asano, K. Kurihara, A. Hamaguchi, H. Kodaira, T. Atsumi, Y. Yamada and K. Tomizuka, *Nucleic Acids Res.*, 2022, **50**, 4840–4859.

399 K. Yamazaki, K. Kubara, Y. Suzuki, T. Hihara, D. Kurotaki, T. Tamura, M. Ito and K. Tsukahara, *Eur. J. Pharm. Biopharm.*, 2023, **183**, 61–73.

400 X. Ye, R. Holland, M. Wood, C. Pasetka, L. Palmer, E. Samaridou, K. McClintock, V. Borisevich, T. W. Geisbert, R. W. Cross and J. Heyes, *Mol. Ther.*, 2023, **31**, 269–281.

401 T. Onizuka, H. Shimizu, Y. Moriwaki, T. Nakano, S. Kanai, I. Shimada and H. Takahashi, *FEBS J.*, 2012, **279**, 2645–2656.

402 A. G. Morell, R. A. Irvine, I. Sternlieb, I. H. Scheinberg and G. Ashwell, *J. Biol. Chem.*, 1968, **243**, 155–159.

403 K. Ozaki, R. T. Lee, Y. C. Lee and T. Kawasaki, *Glycoconjugate J.*, 1995, **12**, 268–274.

404 M. Spiess, *Biochemistry*, 1990, **29**, 10009–10018.

405 J. U. Baenziger and Y. Maynard, *J. Biol. Chem.*, 1980, **255**, 4607–4613.

406 K. Schmidt, T. P. Prakash, A. J. Donner, G. A. Kinberger, H. J. Gaus, A. Low, M. E. Østergaard, M. Bell, E. E. Swayze and P. P. Seth, *Nucleic Acids Res.*, 2017, **45**, 2294–2306.

407 A. A. D’Souza and P. V. Devarajan, *J. Controlled Release*, 2015, **203**, 126–139.

408 T. P. Prakash, M. J. Graham, J. Yu, R. Carty, A. Low, A. Chappell, K. Schmidt, C. Zhao, M. Aghajan, H. F. Murray, S. Riney, S. L. Booten, S. F. Murray, H. Gaus, J. Crosby, W. F. Lima, S. Guo, B. P. Monia, E. E. Swayze and P. P. Seth, *Nucleic Acids Res.*, 2014, **42**, 8796–8807.

409 P. Kandasamy, S. Mori, S. Matsuda, N. Erande, D. Datta, J. L. S. Willoughby, N. Taneja, J. O’Shea, A. Bisbe, R. M. Manoharan, K. Yucius, T. Nguyen, R. Indrakanti, S. Gupta, J. A. Gilbert, T. Racie, A. Chan, J. Liu, R. Hutabarat, J. K. Nair, K. Charisse, M. A. Maier, K. G. Rajeev, M. Egli and M. Manoharan, *J. Med. Chem.*, 2023, **66**, 2506–2523.

410 T. P. Prakash, J. Yu, M. T. Migawa, G. A. Kinberger, W. B. Wan, M. E. Østergaard, R. L. Carty, G. Vasquez, A. Low, A. Chappell, K. Schmidt, M. Aghajan, J. Crosby, H. M. Murray, S. L. Booten, J. Hsiao, A. Soriano, T. Machemer, P. Cauntay, S. A. Burel, S. F. Murray, H. Gaus, M. J. Graham, E. E. Swayze and P. P. Seth, *J. Med. Chem.*, 2016, **59**, 2718–2733.

411 C. Diener, A. Keller and E. Meese, *Trends Genet.*, 2022, **38**, 613–626.

412 Y. Huang, *Mol. Ther.–Nucleic Acids*, 2017, **6**, 116–132.

413 L. N. Kasiewicz, S. Biswas, A. Beach, H. Ren, C. Dutta, A. M. Mazzola, E. Rohde, A. Chadwick, C. Cheng, S. P. Garcia, S. Iyer, Y. Matsumoto, A. V. Khera, K. Musunuru, S. Kathiresan, P. Malyala, K. G. Rajeev and A. M. Bellinger, *Nat. Commun.*, 2023, **14**, 2776.

414 J.-C. Chapuis, R. M. Schmaltz, K. S. Tsosie, M. Belohlavek and S. M. Hecht, *J. Am. Chem. Soc.*, 2009, **131**, 2438–2439.

415 J. Chen, M. K. Ghorai, G. Kenney and J. Stubbe, *Nucleic Acids Res.*, 2008, **36**, 3781–3790.

416 B. R. Schroeder, M. I. Ghare, C. Bhattacharya, R. Paul, Z. Yu, P. A. Zaleski, T. C. Bozeman, M. J. Rishel and S. M. Hecht, *J. Am. Chem. Soc.*, 2014, **136**, 13641–13656.

417 V. Tähtinen, V. Gulumkar, S. K. Maity, A.-M. Yliperttula, S. Siekkinen, T. Laine, E. Lisitsyna, I. Haapalehto, T. Viitala, E. Vuorimaa-Laukkanen, M. Yliperttula and P. Virta, *Bioconjugate Chem.*, 2022, **33**, 206–218.

418 W. Peng and J. C. Paulson, *J. Am. Chem. Soc.*, 2017, **139**, 12450–12458.

419 T. Harumoto, H. Iwai, M. Tanigawa, T. Kubo, T. Atsumi, K. Tsutsumi, M. Takashima, G. Destito, R. Soloff, K. Tomizuka, C. Nycholat, J. Paulson and K. Uehara, *ACS Chem. Biol.*, 2022, **17**, 292–298.

420 G. St-Pierre, S. Pal, M. E. Østergaard, T. Zhou, J. Yu, M. Tanowitz, P. P. Seth and S. Hanessian, *Bioorg. Med. Chem.*, 2016, **24**, 2397–2409.

421 R. L. Redman and I. J. Krauss, *J. Am. Chem. Soc.*, 2021, **143**, 8565–8571.

422 I. S. MacPherson, J. S. Temme, S. Habeshian, K. Felczak, K. Pankiewicz, L. Hedstrom and I. J. Krauss, *Angew. Chem., Int. Ed.*, 2011, **50**, 11238–11242.

423 O. Doluca, J. M. Withers and V. V. Filichev, *Chem. Rev.*, 2013, **113**, 3044–3083.

424 D. Varshney, J. Spiegel, K. Zyner, D. Tannahill and S. Balasubramanian, *Nat. Rev. Mol. Cell Biol.*, 2020, **21**, 459–474.



425 H. Abou Assi, R. El-Khoury, C. González and M. J. Damha, *Nucleic Acids Res.*, 2017, **45**, 11535–11546.

426 M. Marušič, R. N. Veedu, J. Wengel and J. Plavec, *Nucleic Acids Res.*, 2013, **41**, 9524–9536.

427 Z. Li, C. J. Lech and A. T. Phan, *Nucleic Acids Res.*, 2013, **42**, 4068–4079.

428 B. P. Paudel, A. L. Moye, H. Abou Assi, R. El-Khoury, S. B. Cohen, J. K. Holien, M. L. Birrento, S. Samosorn, K. Intharapichai, C. G. Tomlinson, M.-P. Teulade-Fichou, C. González, J. L. Beck, M. J. Damha, A. M. van Oijen and T. M. Bryan, *eLife*, 2020, **9**, e56428.

429 J.-y Liao, I. Anosova, S. Bala, W. D. Van Horn and J. C. Chaput, *Biopolymers*, 2017, **107**, e22999.

430 P. Schofield, A. I. Taylor, J. Rihon, C. D. Peña Martinez, S. Zinn, C.-A. Mattelaer, J. Jackson, G. Dhaliwal, G. Schepers, P. Herdewijn, E. Lescrinier, D. Christ and P. Holliger, *Nucleic Acids Res.*, 2023, **51**, 7736–7748.

431 I. Gómez-Pinto, E. Vengut-Climent, R. Lucas, A. Aviñó, R. Eritja, C. González and J. C. Morales, *Chem. – Eur. J.*, 2013, **19**, 1920–1927.

432 S. Yin, W. Lan, X. Hou, Z. Liu, H. Xue, C. Wang, G.-L. Tang and C. Cao, *J. Med. Chem.*, 2023, **66**, 6798–6810.

433 J. L. Childs-Disney, I. Yildirim, H. Park, J. R. Lohman, L. Guan, T. Tran, P. Sarkar, G. C. Schatz and M. D. Disney, *ACS Chem. Biol.*, 2014, **9**, 538–550.

434 E. Belmonte-Reche, M. Martínez-García, A. Guédin, M. Zuffo, M. Arévalo-Ruiz, F. Doria, J. Campos-Salinas, M. Maynadier, J. J. López-Rubio, M. Freccero, J.-L. Mergny, J. M. Pérez-Victoria and J. C. Morales, *J. Med. Chem.*, 2018, **61**, 1231–1240.

435 L. Yao, L. Wang, S. Liu, H. Qu, Y. Mao, Y. Li and L. Zheng, *Chem. Sci.*, 2024, **15**, 13011–13020.

436 P. Travascio, Y. Li and D. Sen, *Chem. Biol.*, 1998, **5**, 505–517.

437 K. Gehring, J.-L. Leroy and M. Guéron, *Nature*, 1993, **363**, 561–565.

438 I. Zanin, E. Ruggiero, G. Nicoletto, S. Lago, I. Maurizio, I. Gallina and S. N. Richter, *Nucleic Acids Res.*, 2023, **51**, 8309–8321.

439 Y. Feng, X. Ma, Y. Yang, S. Tao, A. Ahmed, Z. Gong, X. Cheng and W. Zhang, *Nucleic Acids Res.*, 2024, **52**, 1243–1257.

440 H. Abou Assi, M. Garavís, C. González and M. J. Damha, *Nucleic Acids Res.*, 2018, **46**, 8038–8056.

441 H. A. Day, P. Pavlou and Z. A. E. Waller, *Bioorg. Med. Chem.*, 2014, **22**, 4407–4418.

442 B. Mir, I. Serrano-Chacón, P. Medina, V. Macaluso, M. Terrazas, A. Gandioso, M. Garavís, M. Orozco, N. Escaya and C. González, *Nucleic Acids Res.*, 2024, **52**, 3375–3389.

443 V. B. Tsvetkov, T. S. Zatsepin, E. S. Belyaev, Y. I. Kostyukevich, G. V. Shpakovski, V. V. Podgorsky, G. E. Pozmogova, A. M. Varizhuk and A. V. Aralov, *Nucleic Acids Res.*, 2018, **46**, 2751–2764.

444 N. Kumar, J. T. Nielsen, S. Maiti and M. Petersen, *Angew. Chem., Int. Ed.*, 2007, **46**, 9220–9222.

445 H. A. Assi, R. W. Harkness, N. Martin-Pintado, C. J. Wilds, R. Campos-Olivas, A. K. Mittermaier, C. González and M. J. Damha, *Nucleic Acids Res.*, 2016, **44**, 4998–5009.

446 C. P. Fenna, V. J. Wilkinson, J. R. P. Arnold, R. Cosstick and J. Fisher, *Chem. Commun.*, 2008, 3567–3569, DOI: [10.1039/B804833A](https://doi.org/10.1039/B804833A).

447 N. Kumar, M. Petersen and S. Maiti, *Chem. Commun.*, 2009, 1532–1534, DOI: [10.1039/B819305C](https://doi.org/10.1039/B819305C).

448 H. Abou Assi, Y. C. Lin, I. Serrano, C. González and M. J. Damha, *Chem. – Eur. J.*, 2018, **24**, 471–477.

449 M. Ghezzo, L. Grigoletto, R. Rigo, P. Herdewijn, E. Groaz and C. Sissi, *Biochimie*, 2023, **214**, 112–122.

450 E. A. Ageely, R. Chilamkurthy, S. Jana, L. Abdullahu, D. O'Reilly, P. J. Jensik, M. J. Damha and K. T. Gagnon, *Nat. Commun.*, 2021, **12**, 6591.

451 B. Li, W. Zhao, X. Luo, X. Zhang, C. Li, C. Zeng and Y. Dong, *Nat. Biomed. Eng.*, 2017, **1**, 0066.

452 P. Monian, C. Shivalila, G. Lu, M. Shimizu, D. Boulay, K. Bussow, M. Byrne, A. Bezigian, A. Chatterjee, D. Chew, J. Desai, F. Favaloro, J. Godfrey, A. Hoss, N. Iwamoto, T. Kawamoto, J. Kumarasamy, A. Lamattina, A. Lindsey, F. Liu, R. Looby, S. Marappan, J. Metterville, R. Murphy, J. Rossi, T. Pu, B. Bhattarai, S. Standley, S. Tripathi, H. Yang, Y. Yin, H. Yu, C. Zhou, L. H. Apponi, P. Kandasamy and C. Vargeese, *Nat. Biotechnol.*, 2022, **40**, 1093–1102.

453 J. Hennessy, B. McGorman, Z. Molphy, N. P. Farrell, D. Singleton, T. Brown and A. Kellett, *Angew. Chem., Int. Ed.*, 2022, **61**, e202110455.

454 A. Saraf, R. Gurjar, S. Kaviraj, A. Kulkarni, D. Kumar, R. Kulkarni, R. Virkar, J. Krishnan, A. Yadav, E. Baranwal, A. Singh, A. Raghuvanshi, P. Agarwal, L. Savergave, S. Singh, H. Pophale, P. Shende, R. B. Shinde, V. Vikhe, A. Karmalkar, B. Deshmukh, K. Giri, S. Deshpande, A. Bulle, M. S. Siddiqui, S. Borthakur, V. R. Tummuru, A. V. Rao, D. Shukla, M. K. Jain, P. Bhardwaj, P. D. Supe, M. K. Das, M. Lahoti and V. Barge, *Nat. Med.*, 2024, **30**, 1363–1372.

455 M. Hollenstein, *Curr. Opin. Chem. Biol.*, 2019, **52**, 93–101.

456 L. B. Huber, K. Betz and A. Marx, *ChemBioChem*, 2023, **24**, e202200521.

457 M. Brunderová, V. Havlíček, J. Matyášovský, R. Pohl, L. Poštová Slavětínská, M. Krömer and M. Hocek, *Nat. Commun.*, 2024, **15**, 3054.

458 S. Arangundy-Franklin, A. I. Taylor, B. T. Porebski, V. Genna, S. Peak-Chew, A. Vaisman, R. Woodgate, M. Orozco and P. Holliger, *Nat. Chem.*, 2019, **11**, 533–542.

459 D. Oberthür, J. Achenbach, A. Gabdulkhakov, K. Buchner, C. Maasch, S. Falke, D. Rehders, S. Klussmann and C. Betzel, *Nat. Commun.*, 2015, **6**, 6923.

460 A. Vater and S. Klussmann, *Drug Discovery Today*, 2015, **20**, 147–155.

461 Y. Xu and T. F. Zhu, *Science*, 2022, **378**, 405–412.

462 O. J. Plante, E. R. Palmacci and P. H. Seeberger, *Science*, 2001, **291**, 1523–1527.

463 A. Pardo-Vargas, M. Delbianco and P. H. Seeberger, *Curr. Opin. Chem. Biol.*, 2018, **46**, 48–55.



464 N. Sabat, A. Stämpfli, M. Flamme, S. Hanlon, S. Bisagni, F. Sladojevich, K. Püntener and M. Hollenstein, *Chem. Commun.*, 2023, **59**, 14547–14550.

465 M. Vanmeert, J. Razzokov, M. U. Mirza, S. D. Weeks, G. Schepers, A. Bogaerts, J. Rozenski, M. Froeyen, P. Herdewijn, V. B. Pinheiro and E. Lescrinier, *Nucleic Acids Res.*, 2019, **47**, 7130–7142.

466 A. R. Hesser, B. M. Brandsen, S. M. Walsh, P. Wang and S. K. Silverman, *Chem. Commun.*, 2016, **52**, 9259–9262.

467 F. Maksudov, E. Kliuchnikov, D. Pierson, M. L. Ujwal, K. A. Marx, A. Chanda and V. Barsegov, *Mol. Ther.–Nucleic Acids*, 2023, **31**, 631–647.

468 I. Anosova, E. A. Kowal, M. R. Dunn, J. C. Chaput, W. D. Van Horn and M. Egli, *Nucleic Acids Res.*, 2015, **44**, 1007–1021.

469 D. Evéquoz, I. E. C. Verhaart, D. van de Vijver, W. Renner, A. Aartsma-Rus and C. J. Leumann, *Nucleic Acids Res.*, 2021, **49**, 12089–12105.

470 J. D. Pyle, S. R. Lund, K. H. O'Toole and L. Saleh, *Cell Rep.*, 2024, **43**, 114631.

